

(12) United States Patent

Cox et al.

(54) RUGGEDIZED ULTRASOUND HYDROGEL INSERT

(71) Applicant: C. R. Bard, Inc., Murray Hill, NJ (US)

Inventors: Jeremy B. Cox, Salt Lake City, UT (US); Glen E. Southard, Park City, UT

(US); Shayne Messerly, Kaysville, UT

(73) Assignee: C. R. Bard, Inc., Murray Hill, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 13/671,382

(22)Filed: Nov. 7, 2012

(65)**Prior Publication Data**

> US 2013/0116571 A1 May 9, 2013

Related U.S. Application Data

- Provisional application No. 61/556,626, filed on Nov. 7, 2011, provisional application No. 61/563,382, filed on Nov. 23, 2011.
- (51) **Int. Cl.** A61K 49/00 (2006.01)(2006.01)A61B 8/00 B29C 39/00 (2006.01)(Continued)
- (52) U.S. Cl.

CPC A61B 8/4281 (2013.01); A61B 8/4444 (2013.01): A61B 8/4483 (2013.01): B29C 39/003 (2013.01); C08J 3/075 (2013.01); A61K 49/22 (2013.01); C08J 2305/00 (2013.01);

C08L 5/00 (2013.01)

(58) Field of Classification Search

CPC A61K 49/22 See application file for complete search history.

(10) Patent No.:

US 9,211,107 B2

(45) Date of Patent:

Dec. 15, 2015

(56)References Cited

U.S. PATENT DOCUMENTS

3,133,244 A 5/1964 Wojtulewicz 3,297,020 A 1/1967 Mathiesen (Continued)

FOREIGN PATENT DOCUMENTS

11/1990 642647 ΑU 1860597 B2 6/1999 (Continued)

OTHER PUBLICATIONS

Rutala, Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008.*


(Continued)

Primary Examiner — Paul Dickinson (74) Attorney, Agent, or Firm — Rutan & Tucker, LLP

(57)ABSTRACT

A ruggedized hydrogel product that is formulated to withstand the effects of high-energy sterilization procedures, such as gamma beam and electron beam sterilization, without significant structural degradation is disclosed. This enables the hydrogel product to be suitable for use in medical applications where sterile components are required. In one embodiment a ruggedized hydrogel product is disclosed and comprises a gel component, water for hydrating the gel component, and at least one free radical absorber component that is capable of absorbing free radicals produced when the hydrogel product is sterilized via a high-energy sterilization procedure. The free radical absorber component in one embodiment includes potassium metabisulfite and ascorbic acid. The ruggedized hydrogel product can be included with an ultrasound probe to provide an acoustically transparent interface between the probe and the skin of a patient.

7 Claims, 9 Drawing Sheets



US 9,211,107 B2

Page 2

(51)	Int. Cl.			4,793,361	Α	12/1988	DuFault
(01)	C08J 3/075		(2006.01)	4,794,930	A	1/1989	Machida et al.
	A61K 49/22		(2006.01)	4,796,632			Boyd et al.
	C08L 5/00		(2006.01)	4,798,588 4,798,598		1/1989	Aillon Bonello et al.
	CU8L 3/00		(2006.01)	4,809,681			Kantrowitz et al.
(56)		Referen	ces Cited	4,809,713		3/1989	Grayzel
(30)		Keleren	ces Citeu	4,813,729			Speckhart
	U.S.	PATENT	DOCUMENTS	4,821,731			Martinelli et al. Sramek
				4,836,214 4,840,622		6/1989	
	3,625,200 A	12/1971		4,849,692		7/1989	
	3,674,014 A 3,817,241 A	6/1974	Tillander et al. Grausz	4,850,358		7/1989	
	3,847,157 A		Caillouette et al.	4,852,580		8/1989	Wood Pidorenko et al.
	3,868,565 A	2/1975	Kuipers	4,856,317 4,856,529		8/1989	
	3,902,501 A		Citron et al.	4,860,757			Lynch et al.
	3,995,623 A 4,003,369 A		Blake et al. Heilman et al.	4,867,169			Machida et al.
	4,063,561 A		McKenna	4,869,263 4,869,718			Segal et al. Brader
	4,072,146 A		Howes	4,887,606			Yock et al.
	4,114,601 A	9/1978		4,887,615	A	12/1989	
	4,149,535 A 4,173,228 A		Volder et al. Van Steenwyk et al.	4,889,128		12/1989	
	4,175,566 A	11/1979		4,899,756 4,901,725		2/1990	Sonek Nappholz et al.
	4,181,120 A		Kunii et al.	4,901,723			Strohl, Jr. et al.
	4,224,949 A		Scott et al.	4,911,173			Terwilliger
	4,244,362 A 4,289,139 A		Anderson Enjoji et al.	4,911,174			Pederson et al.
	4,317,078 A		Weed et al.	4,924,870 4,943,770			Wlodarczyk et al. Ashley-Rollman et al.
	4,327,722 A	5/1982	Groshong et al.	4,945,305		7/1990	
	4,362,166 A		Furler et al.	4,947,852			Nassi et al.
	4,365,639 A 4,380,237 A		Goldreyer Newbower	4,957,111		9/1990	
	4,407,294 A		Vilkomerson	4,961,433			Christian
	4,429,693 A	2/1984	Blake et al.	4,966,148 4,967,753		10/1990 11/1990	Haase et al.
	4,431,005 A		McCormick	4,977,886			Takehana et al.
	4,431,214 A 4,445,501 A		Buffington Bresler	4,989,608			Ratner
	4,459,854 A		Richardson et al.	4,995,396			Inaba et al.
	4,469,106 A	9/1984	Harui	4,998,916 5,005,592			Hammerslag et al. Cartmell
	4,483,343 A		Beyer et al.	5,016,173			Kenet et al.
	4,491,137 A 4,565,201 A	1/1985 1/1986		5,025,799			Wilson
	4,572,198 A		Codrington	5,029,585			Lieber et al.
	4,577,634 A		Gessman	5,040,548 5,042,486		8/1991 8/1991	Pfeiler et al.
	4,582,067 A		Silverstein et al.	5,045,071			McCormick et al.
	4,588,394 A 4,593,687 A	5/1986 6/1986	Schulte et al.	5,046,497		9/1991	
	4,595,012 A		Webler et al.	5,050,607		9/1991 10/1991	Bradley et al.
	4,601,706 A	7/1986		5,057,095 5,058,595		10/1991	
	4,608,989 A	9/1986		5,067,489		11/1991	
	4,608,992 A 4,619,247 A		Hakim et al. Inoue et al.	5,076,278			Vilkomerson et al.
	4,622,644 A	11/1986		5,078,140 5,078,148		1/1992	Nassi et al.
	4,644,960 A		Johans	5,078,149			Katsumata et al.
	4,652,820 A	3/1987 5/1987	Maresca	5,078,678	A		Katıms
	4,665,925 A 4,667,230 A		Arakawa et al.	5,078,714			Katims
	4,674,518 A	6/1987		5,084,022 5,092,341		3/1992	Claude Kelen
	4,676,249 A		Arenas et al.	5,099,845			Besz et al.
	4,681,106 A 4,681,117 A		Kensey et al. Brodman et al.	5,099,850	A		Matsui et al.
	4,688,578 A		Takano et al.	5,100,387		3/1992	
	4,692,148 A		Kantrowitz et al.	5,105,829 5,109,862			Fabian et al. Kelen et al.
	4,697,595 A		Breyer et al.	5,114,401			Stuart et al.
	4,700,997 A 4,706,681 A	10/1987	Strand Breyer et al.	5,121,750			Katims
	4,710,708 A	12/1987		D327,740			Arioka et al.
	4,733,669 A	3/1988	Segal	5,134,370 5,144,955	A A		Jefferts et al. O'Hara
	4,737,794 A	4/1988		5,158,086			Brown et al.
	4,741,356 A 4,742,356 A		Letzo et al. Kuipers	5,160,342	A		Reger et al.
	4,742,336 A 4,753,247 A		Kuipers Kirsner et al.	5,161,536			Vilkomerson et al.
	4,770,185 A	9/1988	Silverstein et al.	5,174,295			Christian et al.
	4,771,788 A	9/1988		5,184,601 5,190,045		2/1993 3/1993	Putman Frazin
	4,781,685 A 4,784,646 A		Lehmann et al. Feingold	5,190,045		3/1993 4/1993	
	4,787,070 A		Suzuki et al.	5,202,365			Dumoulin et al.
	4,787,396 A		Pidorenko	5,211,636			Mische

(56)		Re	feren	ces Cited	5,453,575			O'Donnell et al. Schneider et al.
	Ţ	J.S. PAT	ENT	DOCUMENTS	5,456,256 5,456,718			Szymaitis
				DOCOMENTO	5,464,016			Nicholas et al.
	212,988			White et al.	5,474,065			Meathrel et al.
	214,615 A			Bauer Starr et al	5,476,090 5,480,422		12/1995 1/1996	Ben-Haim
	,217,026 <i>A</i> ,220,924 <i>A</i>			Stoy et al. Frazin	5,487,729			Avellanet et al.
	235,987			Wolfe	5,490,522		2/1996	
	239,464			Blair et al.	5,492,538 5,494,038			Johlin, Jr. Wang et al.
	,240,004 <i>I</i> ,243,995 <i>I</i>			Walinsky et al. Maier	5,500,012			Brucker et al.
	246,007			Frisbie et al.	5,505,205			Solomon et al.
,	247,171			Wlodarczyk et al.	5,509,822 5,513,637			Negus et al. Twiss et al.
	,251,635 <i>A</i> ,255,680 <i>A</i>			Dumoulin et al. Darrow et al.	5,515,853			Smith et al.
	257,636 A			White	5,522,878	A		Montecalvo et al.
	257,979			Jagpal	5,526,812 5,531,664			Dumoulin et al. Adachi et al.
	261,409			Dardel Darrow et al.	5,540,033			Fox et al.
	,265,610 <i>A</i> ,265,614 <i>A</i>			Hayakawa et al.	5,540,230		7/1996	Vilkomerson
	267,569			Lienhard	5,540,681			Strul et al.
	270,810			Nishimura	5,542,938 5,546,949			Avellanet et al. Frazin et al.
	,271,404 ,273,025			Corl et al. Sakiyama et al.	5,546,951			Ben-Haim
	273,042			Lynch et al.	5,558,091			Acker et al.
	274,551			Corby, Jr.	5,568,809 D375,450			Ben-haim Bidwell et al.
	,275,053 <i>E</i> ,279,129 <i>E</i>		/1994 /1994	Wlodarczyk et al.	5,570,671		11/1996	
	279,607			Schentag et al.	5,575,291			Hayakawa et al.
	280,786 A	A 1/	1994	Wlodarczyk et al.	5,583,286			Matsuyama Scovil et al.
	287,331 A			Schindel et al.	5,588,442 5,592,939			Martinelli
	,289,373 <i>I</i> ,292,342 <i>I</i>			Zarge et al. Nelson et al.	5,598,846		2/1997	Peszynski
5,	307,072	4/	1994	Jones, Jr.	5,599,299			Weaver et al.
5,	311,871	A 5/		Yock	5,600,330 5,610,967		2/1997	Moorman et al.
	313,949 <i>A</i> 318,025 <i>A</i>			Yock Dumoulin et al.	5,617,866			Marian, Jr.
	325,860			Seward et al.	5,622,169			Golden et al.
	325,873 A			Hirschi et al.	5,622,170 5,622,184			Schulz Ashby et al.
	,330,496 <i>1</i> ,331,966 <i>1</i>			Alferness Bennett et al.	5,623,931			Wung et al.
	333,614			Feiring	5,624,430		4/1997	Eton et al.
5,	337,678	A 8/	1994	Grout	5,626,554 5,626,870			Ryaby et al.
	,341,807 ,343,865			Nardella Gardineer et al.	5,630,419			Monshipouri et al. Ranalletta
	,345,940 <i>I</i>			Seward et al.	5,644,612	A	7/1997	Moorman et al.
5,	348,020	A 9/	1994	Hutson	5,645,065			Shapiro et al.
	350,352 A			Buchholtz et al. Fields et al.	5,651,047 5,654,864			Moorman et al. Ritter et al.
	,357,961 ,375,596			Twiss et al.	D383,968		9/1997	Bidwell et al.
5,	376,083 A	A 12/	1994	Mische	5,662,115			Torp et al.
	377,678			Dumoulin et al.	5,665,477 5,666,473			Meathrel et al. Wallace
	385,053 <i>A</i> 391,199 <i>A</i>			Wlodarczyk et al. Ben-Haim	5,666,958			Rothenberg et al.
	394,876		1995		5,668,888			Doi et al.
	394,877			Orr et al.	5,669,383 5,669,388			Johnson Vilkomerson
	,395,366 <i>A</i> ,398,683 <i>A</i>			D'Andrea et al. Edwards et al.	5,676,159		10/1997	
	398,691 A			Martin et al.	5,676,673			Ferre et al.
	405,366			Fox et al.	5,691,898 5,694,945			Rosenberg et al. Ben-Haim
	,411,485 <i>A</i> ,413,107 <i>A</i>			Tennican et al. Oakley et al.	5,695,479		12/1997	
	422,478			Wlodarczyk et al.	5,697,377	A	12/1997	Wittkampf
5,	425,367	A 6/	1995	Shapiro et al.	5,699,801 5,700,889			Atalar et al.
	425,370 A			Vilkomerson	5,713,362		12/1997 2/1998	Vilkomerson
	,425,382 <i>A</i> ,427,114 <i>A</i>			Golden et al. Colliver et al.	5,713,363			Seward et al.
5,	429,132	A 7/	1995	Guy et al.	5,713,946			Ben-Haim
	429,617			Hammersmark et al.	5,715,817 5,716,389			Stevens-Wright et al. Walinsky et al.
	,431,641 <i>A</i> ,433,729 <i>A</i>			Grozinger et al. Adams et al.	5,718,241			Ben-Haim et al.
	437,276			Takada	D391,838			Bidwell et al.
5,	437,277	A 8/		Dumoulin et al.	5,722,412	A		Pflugrath et al.
	438,873			Wlodarczyk et al.	5,727,550			Montecalvo
	,443,066 <i>A</i> ,443,489 <i>A</i>			Dumoulin et al. Ben-Haim	5,727,552 5,727,553		3/1998 3/1998	Kyan Saad
	445,150			Dumoulin et al.	5,729,055	A		Manning
5,	450,846 A			Goldreyer	5,729,129	A	3/1998	Acker

US 9,211,107 B2

Page 4

(56)		Referen	ces Cited	5,919,141			Money et al.
	II C	DATENT	DOCUMENTS	5,919,170 5,928,145		7/1999	Woessner Ocali et al.
	U.S	PALENI	DOCUMENTS	5,929,607			Rosenberg et al.
5,729,584	A	3/1998	Moorman et al.	5,931,788			Keen et al.
5,730,129			Darrow et al.	5,931,818		8/1999	Werp et al.
5,731,996		3/1998	Gilbert	5,941,858		8/1999	Johnson
5,733,323			Buck et al.	5,941,889		8/1999	Cermak
5,738,096			Ben-Haim	5,941,904 5,944,022		8/1999 8/1999	Johnston et al. Nardella et al.
5,740,808			Panescu et al.	5,944,022		8/1999	Johnson et al.
5,742,394 5,744,953		4/1998	Hansen Hansen	5,953,683			Hansen et al.
5,748,767		5/1998		5,957,857	A	9/1999	Hartley
5,749,835		5/1998		5,961,923		10/1999	
5,749,938			Coombs	5,967,978			Littmann et al.
5,751,785			Moorman et al.	5,967,980 5,967,991	A A	10/1999	Ferre et al. Gardineer et al.
5,752,513 5,758,650			Acker et al. Miller et al.	5,969,722		10/1999	
5,762,064			Polvani	5,978,705			KenKnight et al.
5,767,669			Hansen et al.	5,982,915			Doi et al.
5,767,960		6/1998	Orman et al.	5,983,126			Wittkampf
5,769,786		6/1998		5,984,908 5,991,693	A	11/1999	Davis et al. Zalewski
5,769,843			Abela et al.	5,997,473		12/1999	Taniguchi et al.
5,769,881 5,771,896			Schroeppel et al. Sliwa, Jr. et al.	5,997,481		12/1999	Adams et al.
5,775,322			Silverstein et al.	6,006,123			Nguyen et al.
5,775,332			Goldman	6,011,988			Lynch et al.
5,779,638		7/1998	Vesely et al.	6,014,473			Hossack et al.
5,782,767			Pretlow, III	6,014,580			Blume et al. Werp et al.
5,785,657			Breyer et al.	6,015,414 6,017,496			Nova et al.
5,792,055 5,795,297		8/1998 8/1998	McKinnon et al.	6,019,724			Gronningsaeter et al.
5,795,298			Vesely et al.	6,019,725			Vesely et al.
5,795,632			Buchalter	6,023,638			Swanson
5,797,849			Vesely et al.	6,026,312			Shemwell et al.
5,800,352			Ferre et al.	6,031,765 6,032,070			Lee et al. Flock et al.
5,800,410			Gawreluk	6,032,070			Larson et al.
5,800,497 5,803,089			Bakels et al. Ferre et al.	6,050,718			Schena et al.
5,810,733			Van Creveld et al.	6,052,610		4/2000	
5,816,245			Manseur et al.	6,052,618			Dahlke et al.
5,817,022	. A	10/1998	Vesely	D424,693		5/2000	
5,817,024			Ogle et al.	6,059,718 6,064,903			Taniguchi et al. Riechers et al.
5,820,549			Marian, Jr.	6,064,905			Webster, Jr. et al.
5,824,031 5,829,444			Cookston et al. Ferre et al.	6,066,094			Ben-Haim
5,830,145		11/1998		6,068,599			Saito et al.
5,831,260		11/1998	Hansen	6,073,043			Schneider
5,833,608		11/1998		6,074,367 6,075,442		6/2000	Hubbell
5,833,622			Meathrel et al.	6,076,007			England et al.
5,835,561 5,836,882		11/1998	Moorman et al.	6,082,366			Andra et al.
5,836,990		11/1998		6,083,170	A		Ben-Haim
5,840,024			Taniguchi et al.	6,099,524			Lipson et al.
5,840,025			Ben-Haim	6,100,026			Nova et al. Naidyhorski
5,840,030			Ferek-Petric et al.	6,102,044 6,107,699			Swanson
5,840,031 5,842,986		11/1998	Avrin et al.	6,112,111		8/2000	
5,843,076			Webster, Jr. et al.	6,113,504		9/2000	Kuesters
5,843,153			Johnston et al.	6,115,624			Lewis et al.
5,844,140		12/1998		6,120,445			Grunwald
5,846,198			Killmann	6,128,174 6,129,668			Ritter et al. Haynor et al.
5,855,553 5,859,893			Tajima et al. Moorman et al.	6,132,378		10/2000	
5,865,748			Co et al.	6,132,379			Patacsil et al.
5,868,673		2/1999		6,135,961			Pflugrath et al.
5,873,822	. A	2/1999	Ferre et al.	6,136,274			Nova et al.
5,876,328			Fox et al.	6,138,681			Chen et al.
5,879,297			Haynor et al.	6,139,496 6,139,502			Chen et al. Fredriksen
5,893,363 5,897,495			Little et al. Aida et al.	6,144,300			Dames et al.
5,897,493 5,899,860			Pfeiffer et al.	6,148,823			Hastings
5,902,238			Golden et al.	6,152,933			Werp et al.
5,907,487			Rosenberg et al.	6,157,853			Blume et al.
5,908,385			Chechelski et al.	6,165,144		12/2000	Talish et al.
5,910,113		6/1999		6,166,496			Lys et al.
5,910,120			Kim et al.	6,166,806		12/2000	
5,913,820		6/1999 6/1999	Bladen et al.	6,167,765 6,172,499		1/2001	Weitzel
5,913,830	A	0/1999	1411168	0,172,499	DI	1/2001	ASHE

(56)	Referen	ces Cited	6,364,823			Garibaldi et al.
	I C DATES IT	DOCER (ENTER	6,364,839			Little et al.
Ĺ	J.S. PATENT	DOCUMENTS	6,366,804 6,368,285		4/2002	Mejia Osadchy et al.
6,173,199 1	R1 1/2001	Gabriel	6,370,411		4/2002	Osadchy et al.
6,173,715		Sinanan et al.	6,373,240		4/2002	Govari
6,175,756		Ferre et al.	6,373,388			Dames et al.
6,176,829 1		Vilkomerson	6,374,134			Bladen et al.
6,193,743 1		Brayton et al.	6,374,670 6,375,606			Spelman et al. Garibaldi et al.
6,200,305 I 6,203,499 I		Berthiaume et al. Imling et al.	6,375,639			Duplessie et al.
6,206,843		Iger et al.	6,377,857		4/2002	Brayton et al.
6,208,884 1		Kumar et al.	6,379,302			Kessman et al.
6,211,626 1		Lys et al.	6,379,303 6,379,307			Seitz et al. Filly et al.
6,211,666 1		Acker Swanson	6,381,485			Hunter et al.
6,212,426 I 6,216,027 I		Willis et al.	6,385,472			Hall et al.
6,216,028 1		Haynor et al.	6,385,476			Osadchy et al.
6,216,029 1		Paltieli	6,398,736			Seward
6,223,087 1		Williams	6,401,723 6,406,442			Garibaldi et al. McFann et al.
6,226,547 I 6,230,046 I		Lockhart et al. Crane et al.	6,412,978			Watanabe et al.
6,233,476		Strommer et al.	6,412,980		7/2002	Lounsberry et al.
6,233,479 1		Haddad et al.	6,417,839		7/2002	
6,238,344		Gamelsky et al.	6,418,332 6,418,335			Mastrototaro et al. Avrin et al.
6,241,673 1		Williams	6,423,002			Hossack
6,246,231 I 6,246,898 I		Vesely et al.	6,423,050			Twardowski
6,248,072		Murkin	6,427,079			Schneider et al.
6,248,074 1	B1 6/2001	Ohno et al.	6,428,551			Hall et al.
6,248,075 1		McGee et al.	6,430,315 6,432,069			Makram-Ebeid Godo et al.
6,253,770 I 6,259,941 I		Acker et al. Chia et al.	6,438,411			Guttman et al.
6,261,231 1		Damphousse et al.	6,442,416			Schultz
6,263,230 1		Haynor et al.	6,443,907			Mansy et al.
6,266,550 1	B1 7/2001	Selmon et al.	6,445,943			Ferre et al.
6,266,551 1		Osadchy et al.	6,459,919 6,463,121		10/2002	Lys et al.
6,266,552 I 6,266,563 I		Slettenmark KenKnight et al.	6,473,167		10/2002	
6,271,833		Rosenberg et al.	6,474,341			Hunter et al.
6,272,371		Shlomo	6,475,152			Kelly, Jr. et al.
6,272,374		Flock et al.	6,475,223 6,477,402			Werp et al. Lynch et al.
6,275,258 1			6,484,118			Govari et al.
6,275,724 I 6,277,077 I		Dickinson et al. Brisken et al.	6,487,916			Gomm et al.
6,284,459 1		Nova et al.	6,491,671			Larson, III et al.
6,285,898 1		Ben-Haim	6,493,573			Martinelli et al.
6,288,704 1		Flack et al.	6,496,715 6,498,944			Lee et al. Ben-Haim et al.
6,292,678 I 6,292,680 I		Hall et al. Somogyi et al.	6,500,141			Irion et al.
6,292,901 1		Lys et al.	6,505,062		1/2003	Ritter et al.
6,293,955 1	B1 9/2001	Houser et al.	6,507,751			Blume et al.
6,296,604 1		Garibaldi et al.	6,508,802 6,512,958		1/2003	Rosengart et al. Swoyer et al.
6,298,261 I 6,304,768 I		Rex Blume et al.	6,514,249			Maguire et al.
6,306,097 1		Park et al.	6,515,657		2/2003	
6,311,082 1	B1 10/2001	Creighton, IV et al.	6,516,212			Bladen et al.
6,315,709 1		Garibaldi et al.	6,516,231 6,516,807			Flammang Panescu et al.
6,315,727 I 6,319,668 I		Coleman et al. Nova et al.	6,517,520			Chang et al.
6,323,769 1		Dames et al.	6,522,906		2/2003	Salisbury, Jr. et al.
6,323,770 1		Dames et al.	6,522,907			Bladen et al.
6,324,416 1			6,522,909			Garibaldi et al.
6,325,540 1		Lounsberry et al.	6,524,303 6,528,954			Garibaldi Lys et al.
6,325,762 I 6,329,139 I		Nova et al.	6,528,991		3/2003	
6,329,916 1		Dames et al.	6,529,761			Creighton, IV et al.
6,330,467 1		Creighton, IV et al.	6,534,982		3/2003	
6,332,089 1		Acker et al.	6,535,625 6,537,192	B1		Chang et al. Elliott et al.
6,332,874 I 6,340,588 I		Eliasen et al. Nova et al.	6,537,192			Creighton, IV et al.
6,340,868 1		Lys et al.	6,538,634			Chui et al.
6,341,231		Ferre et al.	6,540,699		4/2003	
6,346,081 1	B1 2/2002	Vilkomerson	6,542,766			Hall et al.
6,348,911 1		Rosenberg et al.	6,544,251			Crawford
6,350,160 1		Feuersanger et al.	6,546,270			Goldin et al.
6,352,363 I 6,355,026 I		Munger et al.	6,546,279 6,546,787			Bova et al. Schiller et al.
6,361,499 1		Bates et al.	6,549,794			Nadeau, Jr. et al.
5,501,155 1	5,2002		-,,/- !		003	

(56)	Referen	ces Cited	6,799,066			Steines et al.
ŢI	IS PATENT	DOCUMENTS	6,815,651 6,816,266		11/2004 11/2004	Odell Varshneya et al.
O	J.S. TAILIVI	DOCOMENTS	6,817,364			Garibaldi
6,552,841 E	31 4/2003	Lasser et al.	6,832,199			Kucek et al.
6,556,858 E		Zeman	6,834,201 6,844,713		12/2004 1/2005	Gillies et al. Steber et al.
6,562,019 E		Sell Pitris et al.	6,845,142		1/2005	
6,564,087 E 6,569,101 E		Quistgaard et al.	6,856,823		2/2005	
6,571,004 E		Florent et al.	6,860,422			Hull et al.
6,574,518 E		Lounsberry et al.	6,862,467			Moore et al. Elliott et al.
6,575,908 E 6,577,080 E		Barnes et al.	6,869,390 6,875,179			Ferguson et al.
6,577,080 E		Lys et al. Werner et al.	6,879,160		4/2005	
6,584,343 E		Ransbury et al.	6,889,091			Hine et al.
6,593,754 E		Steber et al.	6,895,268			Rahn et al. Garibaldi et al.
6,593,884 E		Gilboa et al.	6,902,528 6,908,433		6/2005	
6,596,791 E 6,597,943 E		Santar et al. Taha et al.	6,911,026			Hall et al.
6,599,249 E		Nordgren et al.	6,923,782			O'Mahony et al.
6,607,488 E		Jackson et al.	6,926,673			Roberts et al.
6,610,058 E			6,934,575 6,936,010			Ferre et al. Fang et al.
6,611,141 E 6,615,071 E		Schulz et al. Casscells, III et al.	6,940,379			Creighton
6,615,155 E		Gilboa	6,941,166		9/2005	MacAdam et al.
6,618,612 E		Acker et al.	6,947,788 6,950,689			Gilboa et al. Willis et al.
6,626,832 E		Paltieli et al.	6,953,754			Machida et al.
6,626,834 E 6,626,902 E		Dunne et al. Kucharczyk et al.	6,958,677		10/2005	
6,630,879 E		Creighton, IV et al.	6,959,214			Pape et al.
6,635,027 E		Cragg et al.	6,962,566 6,968,846		11/2005	Quistgaard et al.
6,645,148 E	32 11/2003	Nguyen-Dinh et al.	6,975,197		11/2005	Viswanathan Creighton, IV
6,648,875 E 6,649,914 E		Simpson et al. Moorman et al.	6,976,962		12/2005	
6,652,506 E		Bowe et al.	6,976,987		12/2005	
6,662,034 E	32 12/2003	Segner et al.	6,980,843			Eng et al.
6,672,308 E		Gaspari	6,980,852 6,980,921		12/2005 12/2005	Jersey-Willuhn et al. Anderson et al.
6,677,752 E 6,679,857 E		Creighton, IV et al. Bastia et al.	6,986,739			Warren et al.
6,684,176 E		Willins et al.	6,999,821	B2	2/2006	Jenney et al.
6,685,644 E	32 2/2004		7,001,355		2/2006	Nunomura et al.
6,687,531 E		Ferre et al.	7,008,418 7,010,338		3/2006	Hall et al. Ritter et al.
6,689,119 E 6,690,963 E		Di Caprio et al. Ben-Haim et al.	7,015,393		3/2006	Weiner et al.
6,690,964 E		Bieger et al.	7,017,584		3/2006	Garibaldi et al.
6,690,968 E			7,019,610 7,020,512		3/2006	Creighton, IV et al.
6,694,167 E		Ferre et al.	D518,574		3/2006 4/2006	Ritter et al. Chaggares
6,695,786 E 6,701,179 E		Wang et al. Martinelli et al.	7,022,075		4/2006	Grunwald et al.
6,701,918 E		Fariss et al.	7,022,082		4/2006	Sonek
6,702,804 E		Ritter et al.	7,026,927			Wright et al. Odell
6,704,590 E 6,709,390 E		Haldeman Marie Pop	7,027,634 7,028,387		4/2006 4/2006	Huynh et al.
6,711,429 E		Gilboa et al.	7,029,446	B2		Wendelken et al.
6,711,431 E	3/2004	Pratt et al.	7,033,603			Nelson et al.
6,719,699 E			D520,139 D520,140			Chaggares Chaggares
6,719,724 E 6,719,756 E		Walker et al. Muntermann	7,038,398			Lys et al.
6,720,745 E		Lys et al.	7,038,657	B2	5/2006	Rosenberg et al.
6,733,511 E	32 5/2004	Hall et al.	7,043,293		5/2006	
6,736,782 E		Pfeiffer et al.	7,054,228 7,066,914			Hickling Andersen
6,738,656 E 6,740,103 E		Ferre et al. Werp et al.	7,066,924			Garibaldi et al.
6,743,177 E		Ito et al.	D525,363		7/2006	
6,754,596 E			7,070,565			Vaezy et al.
6,755,789 E		Stringer et al.	7,072,704 7,082,325			Bucholz Hashimshony et al.
6,755,816 E 6,757,557 E		Ritter et al. Bladen et al.	7,090,639		8/2006	Govari
6,763,261 E		Casscells, III et al.	7,096,148			Anderson et al.
6,764,449 E	32 7/2004	Lee et al.	7,096,870			Lamprich et al.
6,768,496 E		Bieger et al.	7,098,907 7,103,205			Houston et al. Wang et al.
6,772,001 E 6,774,624 E		Maschke et al. Anderson et al.	7,103,205			Laherty et al.
6,783,536 E		Vilsmeier et al.	7,104,980			Da Silva et al.
6,784,660 E			7,106,431		9/2006	Odell
6,785,571 E		Glossop et al.	7,106,479			Roy et al.
6,786,219 E	9/2004	Garibaldi et al.	7,107,105			Bjorklund et al.
6,788,967 E 6,794,667 E		Ben-Haim et al.	7,132,804 7,137,976			Lys et al. Ritter et al.
0,794,007 E	JL 3/2004	1109111	,,131,910	102	11/2000	retter et al.

(56)	Referen	ces Cited	7,751,865 B2	7/2010	Jascob et al.
•			7,766,839 B2		Rogers et al.
U.:	S. PATENT	DOCUMENTS	7,774,051 B2	8/2010	Voth Rothenberg
7 141 012 D2	11/2006	A1 -141	7,794,407 B2 7,798,970 B2		Lo et al.
7,141,812 B2 7,142,905 B2		Appleby et al. Slayton et al.	7,819,810 B2		Stringer et al.
7,148,970 B2			D629,526 S	12/2010	Ladwig et al.
7,153,291 B2		Bierman	D629,527 S		Crunkilton
7,161,453 B2		Creighton, IV	7,850,613 B2 D630,756 S		Stribling Kitayama
7,162,291 B1		Nachaliel	D630,750 S		Kitayama
7,167,738 B2 7,169,107 B2		Schweikard et al. Jersey-Willuhn et al.	7,909,815 B2		Whitmore, III et al.
7,174,201 B2		Govari et al.	7,931,596 B2		Rachlin et al.
7,175,646 B2	2 2/2007	Brenneman et al.	7,976,469 B2		Bonde et al.
7,180,252 B2		Lys et al.	7,998,073 B2 8,118,743 B2		Roth et al. Park et al.
7,184,820 B2 7,189,198 B2		Jersey-Willuhn et al. Harburn et al.	8,388,541 B2		Messerly et al.
7,190,819 B2		Viswanathan	8,388,546 B2		Rothenberg
7,194,295 B2		Vilsmeier	8,437,833 B2		Silverstein
7,204,798 B2		Zdeblick et al.	D684,265 S		Cadera
7,206,064 B2		Rogers et al.	8,478,382 B2 8,512,256 B2		Burnside et al. Rothenberg
7,207,941 B2 7,211,082 B2		Hall et al	8,801,693 B2		He et al.
7,214,191 B2		Stringer et al.	D724,745 S	3/2015	Orome et al.
7,215,326 B2	2 5/2007	Rosenberg	2002/0019447 A1		Renn et al.
7,221,104 B2		Lys et al.	2002/0022777 A1		Crieghton et al.
7,223,256 B2		Bierman	2002/0032391 A1 2002/0055680 A1		McFann et al. Miele et al.
7,229,400 B2 7,231,243 B2		Elliott et al. Tearney et al.	2002/0082559 A1		Chang et al.
7,236,157 B2		Schena et al.	2002/0113555 A1		Lys et al.
7,236,816 B2		Kumar et al.	2002/0114518 A1	8/2002	
7,237,313 B2		Skujins et al.	2002/0123679 A1		Dominguez Seward
7,241,267 B2			2002/0128554 A1 2002/0133079 A1		Sandhu
7,244,234 B2 7,248,032 B1		Ridley et al. Hular et al.	2002/0151789 A1		Mansy et al.
7,248,914 B2		Hastings et al.	2002/0156363 A1		Hunter et al.
7,264,584 B2		Ritter et al.	2002/0156376 A1		Wang et al.
7,270,662 B2		Visram et al.	2002/0165448 A1		Ben-Haim et al.
7,275,682 B2		Excoffier et al.	2002/0165534 A1 2002/0198568 A1		Hayzelden et al. Hafer et al.
7,276,044 B2 7,286,034 B2		Ferry et al. Creighton	2003/0002727 A1		MacMahon
7,291,146 B2		Steinke et al.	2003/0009132 A1	1/2003	Schwartz et al.
7,297,140 B2		Orlu et al.	2003/0011359 A1	1/2003	
7,308,296 B2		Lys et al.	2003/0013966 A1 2003/0018276 A1		Barnes et al. Mansy et al.
7,310,150 B2		Guillermo et al.	2003/0018276 A1 2003/0036696 A1		Willis et al.
7,321,228 B2 7,342,058 B2		Peppmoller et al.	2003/0040671 A1		Somogyi et al.
D566,284 S		Kitayama et al.	2003/0072805 A1		Miyazawa et al.
7,355,716 B2		de Boer et al.	2003/0076281 A1	4/2003	Morgan et al.
7,360,427 B2		Drinkwater et al.	2003/0083698 A1 2003/0088195 A1	5/2003 5/2003	Whitehurst et al. Vardi et al.
7,366,376 B2		Shishkov et al.	2003/000849 A1	5/2003	Jang
7,366,562 B2 7,366,563 B2		Dukesherer et al. Kleen et al.	2003/0114742 A1		Lewkowicz et al.
7,373,271 B1		Schneider	2003/0114777 A1		Griffin et al.
7,382,949 B2	6/2008	Bouma et al.	2003/0120150 A1		Govari
7,418,169 B2		Tearney et al.	2003/0120154 A1 2003/0139661 A1		Sauer et al. Kimchy et al.
7,447,408 B2 7,452,331 B1		Bouma et al.	2003/0149328 A1		Elliott et al.
7,452,351 B1		Stern et al.	2003/0149359 A1	8/2003	
D585,556 S	1/2009	Kosaku	2003/0152290 A1	8/2003	Odell
7,479,141 B2		Kleen et al.	2003/0160721 A1 2003/0163037 A1		Gilboa et al. Bladen et al.
7,534,223 B2		Boutilette et al. Tearney et al.	2003/0103037 A1 2003/0171691 A1		Casscells et al.
7,538,859 B2 7,547,282 B2		Lo et al.	2003/0173953 A1	9/2003	
7,551,293 B2		Yelin et al.	2003/0184544 A1		Prudent
D599,909 S		Rinott et al.	2003/0191392 A1		Haldeman
D603,050 S	10/2009		2003/0191460 A1 2003/0195420 A1		Hobbs et al. Mendlein et al.
7,599,730 B2		Hunter et al.	2003/0193420 A1 2003/0199746 A1		Fuimaono et al.
D603,520 S 7,635,336 B1		Ninomiya et al.	2003/0208142 A1		Boudewijn et al.
7,637,163 B2		Fetzer et al.	2003/0216639 A1	11/2003	Gilboa et al.
7,640,053 B2	2 12/2009	Verin	2003/0220557 A1	11/2003	Cleary et al.
7,651,469 B2		Osborne et al.	2003/0220578 A1		Ho et al.
7,652,080 B2		Peppmoller et al.	2003/0229298 A1		Iwami et al.
D609,814 S 7,665,893 B2		Banryu Buchalter	2003/0233042 A1 2004/0015070 A1	1/2003	Ashe Liang et al.
7,668,583 B2		Fegert et al.	2004/0013070 A1 2004/0024301 A1		Hockett et al.
7,699,782 B2		Angelsen et al.	2004/0030319 A1		Korkor et al.
7,727,192 B2		Tokumoto et al.	2004/0043688 A1*	3/2004	Soerens et al 442/149

US 9,211,107 B2

Page 8

(56)	Referen	ices Cited	2005/0222532			Bertolero et al.
II C	DATENIT	DOCUMENTS	2005/0240102 2005/0256398			Rachlin et al. Hastings et al.
0.5.	PALENT	DOCUMENTS	2005/0256541			Stypulkowski
2004/0054278 A1	3/2004	Kimchy et al.	2006/0015003			Moaddes et al.
2004/0082916 A1	4/2004		2006/0025677			Verard et al.
2004/0087877 A1		Besz et al.	2006/0058633			Hoshino et al.
2004/0088136 A1	5/2004		2006/0068074 2006/0084867			Stefandl Tremblay et al.
2004/0097803 A1 2004/0097804 A1	5/2004	Panescu	2006/0034807			Maschke et al.
2004/0097805 A1		Verard et al.	2006/0116578			Grunwald et al.
2004/0097806 A1		Hunter et al.	2006/0149134			Soper et al.
2004/0116809 A1		Chow et al.	2006/0173329 2006/0173407			Irioka et al.
2004/0127805 A1		MacAdam et al.	2006/0175407			Shaughnessy et al. Jaramaz et al.
2004/0131998 A1 2004/0133111 A1		Marom et al. Szczech et al.	2006/0176242			Vaezy et al.
2004/0133111 A1 2004/0133130 A1		Ferry et al.	2006/0188487	A1	8/2006	Thomas et al.
2004/0135069 A1	7/2004	Odell	2006/0206037			Braxton
2004/0138564 A1		Hwang et al.	2006/0211944 2006/0224188			Mauge et al. Libbus et al.
2004/0138570 A1		Nita et al.	2006/0224188			Danek et al.
2004/0147837 A1 2004/0150963 A1		Macaulay et al. Holmberg et al.	2006/0264756			Lo et al.
2004/0152972 A1		Hunter	2006/0276867			Viswanathan
2004/0155609 A1		Lys et al.	2007/0010753			MacAdam
2004/0158140 A1		Fuimaono et al	2007/0016007 2007/0016013		1/2007	Govari et al.
2004/0171924 A1 2004/0176688 A1		Mire et al. Haldeman	2007/0016068			Grunwald et al.
2004/0176688 A1 2004/0186461 A1		DiMatteo	2007/0016069			Grunwald et al.
2004/0199069 A1		Connelly et al.	2007/0016070			Grunwald et al.
2004/0210289 A1	10/2004	Wang et al.	2007/0016072			Grunwald et al.
2004/0230271 A1		Wang et al	2007/0049822 2007/0049846			Bunce et al. Bown et al.
2004/0231065 A1 2004/0234453 A1	11/2004	Daniel et al. Smith	2007/0055141			Kruger et al.
2004/0253365 A1		Warren et al.	2007/0055142			Webler
2004/0254470 A1		Drinkwater et al.	2007/0060992			Pappone
2004/0260174 A1	12/2004		2007/0062544			Rauk Bergstrom et al.
2004/0267086 A1		Anstadt et al.	2007/0073155 2007/0087038			Park et al. Richardson et al.
2005/0004450 A1		Ben-Haim et al.	2007/0087038			Maschke
2005/0021019 A1 2005/0033150 A1		Hashimshony et al. Takahashi et al.	2007/0100285			Griffin et al.
2005/0033177 A1		Rogers et al.	2007/0112282			Skujins et al.
2005/0038355 A1		Gellman et al.	2007/0123769			Fuller et al.
2005/0049486 A1		Urquhart et al.	2007/0123805 2007/0129770		6/2007	Shireman et al.
2005/0049510 A1 2005/0063194 A1		Haldeman et al. Lys et al.	2007/0125770		6/2007	
2005/0005194 A1 2005/0070788 A1		Wilson et al.	2007/0135886			Maschke
2005/0075561 A1		Golden	2007/0156205			Larson et al.
2005/0085716 A1		Hamm et al.	2007/0161915		7/2007	
2005/0085718 A1		Shahidi	2007/0167738 2007/0167801			Timinger et al. Webler et al.
2005/0085720 A1 2005/0101868 A1		Jascob et al. Ridley et al.	2007/0167831			Huang et al.
2005/0101869 A1		Burba et al.	2007/0167997			Forsberg et al.
2005/0105081 A1	5/2005	Odell	2007/0197905			Timinger et al.
2005/0105101 A1	5/2005	Duling et al.	2007/0208255		9/2007	Ridley et al. Viswanathan
2005/0112135 A1 2005/0113669 A1		Cormier et al. Helfer et al.	2007/0225589 2007/0225610			Mickley et al.
2005/0113676 A1		Weiner et al.	2007/0232882			Glossop et al.
2005/0113676 A1 2005/0113700 A1		Yanagihara et al.	2007/0238984	Al		Maschke et al.
2005/0113873 A1		Weiner et al.	2007/0239018			Fetzer et al.
2005/0113874 A1		Connelly et al.	2007/0244413 2007/0247454		10/2007	Rahn et al.
2005/0113876 A1 2005/0131291 A1		Weiner et al. Floyd et al.	2007/0247434		10/2007	
2005/0149002 A1		Wang et al.	2007/0265526			Govari et al.
2005/0151489 A1		Lys et al.	2007/0280974			Son et al.
2005/0154308 A1		Quistgaard et al.	2007/0282196			Birk et al.
2005/0159644 A1		Takano	2007/0282197 2007/0299352			Bill et al. Harlev et al.
2005/0159790 A1 2005/0165301 A1	7/2005	Shalev Smith et al.	2008/0008745			Stinchcomb et al.
2005/0165313 A1		Byron et al.	2008/0009720		1/2008	Schefelker et al.
2005/0175665 A1	8/2005	Hunter et al.	2008/0015442			Watson et al.
2005/0175703 A1		Hunter et al.	2008/0027320			Bolorforosh et al.
2005/0178395 A1		Hunter et al.	2008/0045908 2008/0051626			Gould et al. Sato et al.
2005/0178396 A1 2005/0182295 A1		Hunter et al. Soper et al.	2008/0031626			Denison et al.
2005/0203368 A1	9/2005		2008/0081938			Gaudiani
2005/0203396 A1		Angelsen et al.	2008/0097232			Rothenberg
2005/0205081 A1	9/2005	Barker et al.	2008/0108949			Beasley et al.
2005/0215901 A1		Anderson et al.	2008/0114095			Peppmoller et al.
2005/0215945 A1	9/2005	Harris et al.	2008/0114370	Al	5/2008	Schoenefeld

(56)	References Cited	2010/0318		Grunwald
U.S	PATENT DOCUMENTS	2010/0333 2011/0013	5527 A1 1/2011	Rothenberg Heasty et al.
2009/0125772 41	5/2008 Store at al	2011/0015 2011/0040		Cox et al. Matsumura
2008/0125772 A1 2008/0139944 A1	5/2008 Stone et al. 6/2008 Weymer et al.	2011/0040		Dietz et al.
2008/0146939 A1	6/2008 McMorrow et al.	2011/0052		Stinchcomb et al.
2008/0146940 A1	6/2008 Jenkins et al.	2011/0060 2011/0083		Tupin, Jr. et al. Lindekugel et al.
2008/0152204 A1 2008/0154100 A1	6/2008 Huo et al. 6/2008 Thalmeier et al.	2011/0083		Tremper et al.
2008/0166453 A1	7/2008 Steele et al.	2011/017	1286 A1 7/2011	Cecile et al.
2008/0171934 A1	7/2008 Greenan et al.	2011/0190		Grunwald Bergeron 252/194
2008/0183075 A1 2008/0200754 A1	7/2008 Govari et al. 8/2008 Buchalter	2011/02/3		Burnside et al.
2008/0228082 A1	9/2008 Scheirer et al.	2011/029	5108 A1 12/2011	Cox et al.
2008/0255404 A1	10/2008 Nogawa et al.	2011/0313		Lindekugel et al.
2008/0255475 A1	10/2008 Kondrosky et al.	2012/0046 2012/0059		Powers et al. Grunwald
2008/0275765 A1 2009/0005675 A1	11/2008 Kuchar 1/2009 Grunwald et al.	2012/0095	319 A1 4/2012	! Kondrosky et al.
2009/0018497 A1	1/2009 Birchard et al.	2012/0108	3950 A1 5/2012	He et al.
2009/0018574 A1	1/2009 Martin	2012/0143 2012/0165		Silverstein et al. Orome et al.
2009/0024018 A1 2009/0036774 A1	1/2009 Boyden et al. 2/2009 Weng et al.	2012/010.		Messerly et al.
2009/00367/4 A1 2009/0036790 A1	2/2009 Weng et al. 2/2009 Landesberg et al.	2013/0006		Wilkes et al.
2009/0043205 A1	2/2009 Pelissier et al.	2013/0060		Messerly et al.
2009/0076327 A1	3/2009 Ohki	2013/0123		Rothenberg
2009/0082661 A1 2009/0084382 A1	3/2009 Saladin et al. 4/2009 Jalde et al.	2014/0180	J110 A1 0/2012	Lindekugel et al.
2009/0101577 A1	4/2009 Fulkerson et al.		FOREIGN PATI	ENT DOCUMENTS
2009/0118612 A1	5/2009 Grunwald et al.		TOREMONTAL	ENT DOCUMENTS
2009/0118706 A1 2009/0124901 A1	5/2009 Schweikert et al. 5/2009 Fink et al.	AU	20009592	9/2000
2009/0124901 A1 2009/0136099 A1	5/2009 Prink et al. 5/2009 Boyden et al.	AU AU	20015250	6/2001
2009/0143736 A1	6/2009 Mittermeyer et al.	AU AU	768362 B2 2001229024 B2	
2009/0149748 A1	6/2009 Lenhardt et al.	AU	2001283703 B2	
2009/0156926 A1 2009/0163810 A1	6/2009 Messerly et al. 6/2009 Kanade et al.	AU	2006202149	6/2006
2009/0171217 A1	7/2009 Kim et al.	AU AU	2006904933 2006283022 B2	9/2006 2/2012
2009/0177083 A1	7/2009 Matsumura	CA	2420676	2/2002
2009/0177090 A1 2009/0177092 A1	7/2009 Grunwald et al. 7/2009 Riechers et al.	CN	1672649 A	9/2005
2009/0203989 A1	8/2009 Burnside et al.	CN CN	102209490 A 102802514 A	10/2011 11/2012
2009/0204113 A1	8/2009 Macadam et al.	CN	102802314 A 102821679 A	12/2012
2009/0209950 A1 2009/0227952 A1	8/2009 Starksen 9/2009 Blakstvedt et al.	CN	103037761 A	4/2013
2009/0227932 AT 2009/0234328 AT	9/2009 Blakstvedt et al. 9/2009 Cox et al.	CN	103037762 A	4/2013
2009/0258171 A1	10/2009 Uang	CN CN	103118591 A 103228219 A	5/2013 7/2013
2009/0259124 A1	10/2009 Rothenberg	DE	4319033 C1	6/1994
2009/0262982 A1 2009/0275828 A1	10/2009 Markowitz et al. 11/2009 Shachar et al.	EP	0359697	3/1990
2009/0297441 A1	12/2009 Canham et al.	EP EP	0362821 0399536 A1	4/1990 11/1990
2010/0004543 A1	1/2010 Ahlund et al.	EP	0823261 A2	
2010/0004547 A1 2010/0016726 A1	1/2010 Scholz et al. 1/2010 Meier	EP	0928976 A2	
2010/0016726 A1 2010/0036227 A1	2/2010 Cox et al.	EP EP	1311226 A1 1504713 A1	5/2003 2/2005
2010/0049062 A1	2/2010 Ziv	EP	2313143 A1	
2010/0055153 A1 2010/0055184 A1	3/2010 Majmudar 3/2010 Zeitels et al.	EP	2440122 A1	4/2012
2010/0053184 A1 2010/0057157 A1	3/2010 Zeners et al. 3/2010 Govari et al.	EP EP	2464407 A2	
2010/0060472 A1	3/2010 Kimura et al.	EP EP	2482719 A1 2575610 A1	
2010/0083719 A1	4/2010 Peppmoller et al.	EP	2575611 A1	
2010/0094116 A1 2010/0106011 A1	4/2010 Silverstein 4/2010 Byrd et al.	EP	2603145 A2	
2010/0114573 A1	5/2010 Huang et al.	EP FR	2605699 A2 2545349	6/2013 11/1984
2010/0126149 A1	5/2010 Kondou	JР	01097440	4/1989
2010/0143119 A1 2010/0179429 A1	6/2010 Kooijman et al. 7/2010 Ho et al.	JP	03173542 A	7/1991
2010/0175425 A1 2010/0185097 A1	7/2010 Hall	JP JP	4090741 9-503054	8/1992 3/1997
2010/0198048 A1	8/2010 Togawa	JP JP	9-303034 09-094298 A	3/1997 4/1997
2010/0204569 A1	8/2010 Burnside et al.	JP	10043310	2/1998
2010/0217116 A1 2010/0222663 A1	8/2010 Eck et al. 9/2010 Wilder et al.	JP	10290839 A	11/1998
2010/0222664 A1	9/2010 Lemon et al.	JP JP	11128237 A 2001161683	5/1999 6/2001
2010/0234733 A1	9/2010 Wahlheim	JP	2001340334	12/2001
2010/0249598 A1	9/2010 Smith et al.	JP	2003501127 A	1/2003
2010/0258033 A1 2010/0273895 A1	10/2010 Yang et al. 10/2010 Stinchcomb et al.	JP JP	2003061752 A 2003299654	3/2003 10/2003
2010/0298702 A1	11/2010 Rogers et al.	JP	2003299034	11/2003
2010/0317981 A1	12/2010 Grunwald	JP	2002520893	2/2004

(56)	References Cited	WO 2011051406 A1 5/2011
	FOREIGN PATENT DOCUMENTS	WO 2011064209 A1 6/2011 WO 2011084593 A2 7/2011
	FOREIGN PATENT DOCUMENTS	WO 2011097312 A1 8/2011
JР	2004505748 T 2/2004	WO 2011128052 A2 10/2011
JP	2004515298 A 5/2004	WO 2011150358 A1 12/2011
Ъ	2006508744 A 3/2006	WO 2012021542 A2 2/2012 WO 2012024577 A2 2/2012
JP JP	5010604 6/2012 2012-529929 11/2012	WO 2012058461 A1 5/2012
JP	2012-529929 11/2012 2013-518676 A 5/2013	WO 2012060562 A2 5/2012
ĴР	2013-535301 A 9/2013	WO 2012083245 A1 6/2012
WO	9112836 A1 9/1991	WO 2012088535 A1 6/2012
WO	9203090 3/1992	WO 2013006817 A1 1/2013 WO 2013070775 A1 5/2013
WO WO	9403159 A1 2/1994 9404938 3/1994	WO 2013188833 A2 12/2013
wo	9605768 A1 2/1996	WO 2014134171 A1 9/2014
WO	9607352 A1 3/1996	OTHER PUBLICATIONS
WO	9641119 12/1996	OTHER FODLICATIONS
WO WO	9729683 A1 8/1997 9743989 A1 11/1997	PCT/US2012/063956 filed Nov. 7, 2012 International Seach Report
WO	9916495 A1 4/1999	and Written Opinion dated Apr. 1, 2013.
WO	9949407 A1 9/1999	PCT/US2009/056567 filed Sep. 10, 2009 International Preliminary
WO	0019906 4/2000	Report on Patentability dated Mar. 15, 2011.
WO WO	0040155 7/2000 0074775 A1 12/2000	PCT/US2009/056567 filed Sep. 10, 2009 Search Report dated Nov.
WO	0074775 A1 12/2000 0176479 A1 10/2001	6, 2009.
wo	0215973 A1 2/2002	PCT/US2009/056567 filed Sep. 10, 2009 Written Opinion dated
WO	0225277 A1 3/2002	Nov. 6, 2009.
WO	03061752 7/2003	PCT/US2010/038555 filed Jun. 14, 2010 Search Report dated Oct. 5,
WO WO	03077759 A1 9/2003 2004049970 A2 6/2004	2010.
WO	2005033524 A1 4/2005	PCT/US2010/038555 filed Jun. 14, 2010 Written Opinion dated Oct.
WO	2005033574 A1 4/2005	5, 2010.
WO	2005117690 A1 12/2005	PCT/US2010/045084 filed Aug. 10, 2010 International Preliminary
WO WO	2006074509 A1 7/2006	Report on Patentability dated Feb. 23, 2012. PCT/US2010/045084 filed Aug. 10, 2010 Search Report dated Apr.
WO	2006074510 A1 7/2006 2006078677 A2 7/2006	14, 2011.
WO	2006103661 A2 10/2006	PCT/US2010/045084 filed Aug. 10, 2010 Written Opinion dated Apr.
WO	2006111056 A1 10/2006	14, 2011.
WO	2007002541 A2 1/2007	PCT/US2010/050773 filed Sep. 29, 2010 Search Report dated Jan.
WO WO	2007005976 A1 1/2007 2007014447 A1 2/2007	24, 2011.
WO	2007034196 A2 3/2007	PCT/US2010/050773 filed Sep. 29, 2010 Written Opinion dated Jan.
WO	2007067324 A1 6/2007	24, 2011.
WO	2007069168 A2 6/2007	PCT/US2010/051917 filed Oct. 8, 2010 Search Report dated Nov. 29,
WO WO	2007109123 A2 9/2007 2007126536 A2 11/2007	2010.
wo	2007144894 A1 12/2007	PCT/US2010/051917 filed Oct. 8, 2010 Written Opinion dated Nov.
WO	2008005480 A1 1/2008	29, 2010.
WO	2008024596 A2 2/2008	PCT/US2011/023497 filed Feb. 2, 2011 Search Report dated Jun. 6,
WO WO	2008028253 3/2008 2008083111 7/2008	2011. PCT/US2011/023497 filed Feb. 2, 2011 Written Opinion dated Jun.
WO	2008033111 7/2008 2008118992 A1 10/2008	6, 2011.
WO	2008126074 A2 10/2008	PCT/US2011/038391 filed May 27, 2011 International Preliminary
WO	2008131017 A2 10/2008	Report on Patentability and Written Opinion dated Dec. 4, 2012.
WO WO	2008136008 A2 11/2008 2009002514 A2 12/2008	PCT/US2011/038391 filed May 27, 2011 International Search
WO	2009002314 A2 12/2008 2009009064 A1 1/2009	Report dated Sep. 21, 2011.
WO	2009057774 A1 5/2009	PCT/US2011/038415 filed May 27, 2011 International Preliminary
WO	2009070616 A2 6/2009	Report on Patentability dated Dec. 13, 2012.
WO WO	2009100158 A1 8/2009 2009123810 A2 10/2009	PCT/US2011/038415 filed May 27, 2011 International Search Report dated Sep. 28, 2011.
WO	2009123819 A2 10/2009 2009126340 A1 10/2009	PCT/US2011/038415 filed May 27, 2011 Written Opinion dated Sep.
WO	2009129475 A1 10/2009	28, 2011.
WO	2009129477 A1 10/2009	PCT/US2011/047127 filed Aug. 9, 2011 International Preliminary
WO	2009134605 A2 11/2009	Report on Patentability dated Apr. 18, 2013.
WO WO	2009137262 A2 11/2009 2010002313 A1 1/2010	PCT/US2011/047127 filed Aug. 9, 2011 International Search Report
wo	2010018500 A1 2/2010	dated Feb. 29, 2012.
WO	2010022370 A1 2/2010	PCT/US2011/047127 filed Aug. 9, 2011 Written Opinion dated Feb. 29, 2012.
WO	2010027349 A1 3/2010	PCT/US2011/048403 filed Aug. 19, 2011 International Search
WO WO	2010027471 A2 3/2010 2010030820 A1 3/2010	Report dated Dec. 15, 2011.
WO	2010132857 A1 11/2010	PCT/US2011/048403 filed Aug. 19, 2011 Written Opinion dated
wo	2010143196 A1 12/2010	Dec. 15, 2011.
WO	2010144922 A1 12/2010	PCT/US2011/052793 filed Sep. 22, 2011 International Preliminary
WO	2011019760 A2 2/2011	Report on Patentability dated Apr. 4, 2013.
WO WO	2011041450 A1 4/2011 2011044421 A1 4/2011	PCT/US2011/052793 filed Sep. 22, 2011 International Search Report dated Jan. 6, 2012.
WO	2011044421 A1 4/2011	report dated sail, 0, 2012.

OTHER PUBLICATIONS

PCT/US2011/052793 filed Sep. 22, 2011 Written Opinion dated Jan. 6, 2012.

PCT/US2011/058138 filed Oct. 27, 2011 International Preliminary Report on Patentability dated May 10, 2013.

PCT/US2011/058138 filed Oct. 27, 2011 International Search Report dated Feb. 7, 2012.

PCT/US2011/058138 filed Oct. 27, 2011 Written Opinion dated Feb. 7, 2012.

PCT/US2011/067268 filed Dec. 23, 2011 International Preliminary Report on Patentability dated Jul. 4, 2013.

PCT/US2011/067268 filed Dec. 23, 2011 International Search Report and Written Opinion dated Apr. 27, 2012.

PCT/US2012/045814 filed Jul. 6, 2012 International Search Report and Written Opinion dated Oct. 1, 2012.

Pennington, C.R., Right Atrial Thrombus: a Complication of Total Parenteral Nutrition, British Medical Journal, pp. 446-447, vol. 295, Aug. 15, 1987.

Petersen, J et al, Silicone Venous Access Devices Positioned with their Tip High in the Superior Vena Cava are More Likely to Malfunction, Am J Surg, pp. 38-41, vol. 178 No. 1, Jul. 1999.

Pittiruti, et al, Intracavitary EKG Monitoring: A reliable method for controlling tip position during and after PICC Insertion presentation in Catholic University, Rome, Italy in 2008.

Pittiruti, et al. "The EKG Method for Positioning the Tip of PICCs: Results from Two Preliminary Studies." JAVA, vol. 13, No. 4, pp. 179-185, 2008.

Polos, PG et al, Tips for Monitoring the Position of a Central Venous Catheter—How Placement can go awry—even when the anatomy is normal, J Crit Illn, pp. 660-674, vol. 8 No. 6, Jun. 1993 (Abstract only).

Pop, Gheorghe A. et al., Catheter-based impedance measurements in the right atrium for continuously monitoring hematocrit and estimating blood viscosity changes; an in vivo feasibility study in swine, Biosensors and Bioelectronics 19 (2004) 1685-1693.

Popp, M. B. et al., Accuracy of implanted port placement with the use of the electromagnetic CathTrack® catheter locator system, The Journal of Vascular Access 2005; 6: 9-12.

Randolph AG et al, Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature, Critcal Care Medicine, pp. 2053-2058, vol. 24, Dec. 1996.

Reece, A et al, Posititioning Long Lines: Contrast Versus Plain Radiography, Arch Dis Child Fetal Neonatal Ed, pp. 129-130, vol. 84 No. 2, Mar. 2001.

Reynolds, N et al, Assessment of Distal Tip Position of Long Term Central Venous Feeding Catheters using Transesophageal Echocardiology, JPEN J Parenter Enteral Nutr, pp. 39-41, vol. 25 No. 1, Jan.-Feb. 2001.

Ruschulte, Heiner et al, Prevention of Central Venous Catheter related infections with chlorhex idine gluconate impregnated wound dressings: A randomized controlled trial, presented as an abstract at the Annual meeting of the European Society of Anaesthesiologists (ESA) in Madrid, Spain in Jun. 2006, 12 pages, Annals of Hematology, Jul. 14, 2008.

Rutherford, J. S. et al., Depth of Central Venous Catheterization: An Audit of Practice in a Cardiac Surgical Unit, Anaesth Intens Care 1994; 22: 267-271.

Sacolick, et al. "Electromagnetically Tracked Placement of a Peripherally Inserted Central Catheter." SPIE Medical Imaging, 2004 Proceedings.

Salem, et al. "A New Peripherally Implanted Subcutaneous Permanent Central Venous Access Device for Patients Requiring Chemotherapy." Journal of Clinical Oncology, vol. 11, No. 11, pp. 2181-2185, Nov. 1993.

Savary, D et al, Intra-atrial Monitoring to Add Insertion of a Central Venous Line in Pre-Hospital Emergency Care Journal Europeen des Urgences, pp. 75-78, vol. 17 No. 2, 2004.

Schafer et al. "Incorrect placement of a vena cava catheter and its prevention by intra-atrial ECG." Anaesthesist. Jan. 1988;37(1):49-51

Schummer, et al. "Central Venous Catheters—The inability of 'intraatrial ECG' to prove adequate positioning." British Journal of Anaesthesia, vol. 93, No. 2, pp. 193-198, 2004.

Kjelstrup T et al, Positioning of Central Venous Catheters using ECG, Tidssk Nor Laegeforen, pp. 599-601, vol. 111 No. 5, Feb. 1999 (Abstract only).

Kofler, Julia, et al., Epinephrine application via an endotracheal airway and via the Combitube in esophageal position, Critical Care Medicine: May 2000, vol. 28: Issue 5, pp. 1445-1449.

Konings, MK, et al., Development of an intravascular impedance catheter for detection of fatty lesions in arteries, IEEE Trans Med Imaging Aug. 1997; 16(4):439-46.

Kowalski, CM et al, Migration of Central Venous Catheters: Implications for Initial Catheter Tip Positioning, J Vasc Interv Radiol, pp. 443-447, vol. 8 No. 3, May-Jun. 1997.

Leowenthal, MR et al, The Peripherally Inserted Central Catheter (PICC): A Prospective Study of its Natural History after Fossa Insertion, Anaesth Intensive Care, pp. 21-24; vol. 30 No. 1, Feb. 2002.

Lepage Ronan et al. ECG Segmentation and P-wave Feature Extraction: Application to Patients Prone to Atrial Fibrillation, IEEE/EMBS Proceedings, 23rd Annual Conference, Istanbul, Turkey, Oct. 25-28, 2001.

Liu , Ji-Bin et al, Catheter-Based Intralumincal Sonography, J Ultrasound Med, pp. 145-160, vol. 23, 2004.

Lucey, B et al, Routine Chest Radiographs after Central Line Insertion: Mandatory Postprocedural Evaluation or Unnecessary Waste of Resources?, Cardiovasc Intervent Radiol, pp. 381-384, vol. 22 No. 5, Sep.-Oct. 1999.

Lum, Phillip, A New Formula-Based Measurement Guide for Optimal Positioning of Central Venous Catheters, JAVA, vol. 9, No. 2, pp. 80-85, 2004.

Lynch, RE et al, A Procedure for Placing Pediatric Femoral Venous Catheter Tips near the Right Atrium, Pediatr Emerg Care, pp. 130-132, vol. 18 No. 2, Apr. 2002.

Madan, et al. "Right Atrial Electrocardiography: A Technique for the Placement of Central Venous Catheters for Chemotherapy or Intravenous Nutrition." British Journal of Surgery, vol. B1, pp. 1604-1605, 1994.

Madias, John E, Intracardiac (Superior Vena Cava/Right Atrial) ECGs using Saline Solution as the Conductive Medium for the Proper Positioning of the Shiley Hemodialysis Catheter: Is it Not Time to Forego the Postinsertion Chest Radiograph?, pp. 2363-2367, CHEST, 2003.

Markovich, Mary B., Central Venous Catheter Tip Placement: Determination of Posterior Malposition-A Case Study, JAVA, vol. 11, No. 2, pp. 85-89, 2006.

Martin, Roy W, An Ultrasoundic Catheter for Intravascular Measurement of Blood Flow: Technical Details, IEEE Transactions on Sonics and Ultrasonics, vol. SU-27, No. 6, pp. 277-286, Nov. 1980.

McDonnall, "Intra-Atrial Electrocardiography (ECG) for Catheter Placement." Literature review prepared for Bard Access Systems, Oct. 2007.

McGee et al., "Accurate Placement of Central Venous Catheters: A Prospective, Randomize, Multicenter Trail." Critical Care Medicine, vol. 21 No. 8, Aug. 1993.

MedGraphics, CardioPerfect® Resting/Stress ECG System, 3 pages, 2001.

Michenfelder, John et al, Air Embolism During Neurosurgery—An Evaluation of Right-Atrial Catheters for Diagnosis and Treatment, JAMA, pp. 1353-1358, vol. 208, No. 8, May 26, 1969.

Michenfelder, John et al, Air Embolism During Neurosurgery. A New Method of Treatment, Anesthesia and Analgesia. Current Researches, pp. 390-395, vol. 45, No. 4, Jul.-Aug. 1966.

MICROBIRDTM Miniaturized DC Magnetic Sensors for Intra-body Navigation and Localization, Specifications, 2005.

MICRONIX CathRite™ Cardiac Access Device Brochure. Jun. 2004

Micronix Pty Ltd "CathRite" Guiding Styled Core Manufacturing, Jun. 15, 2006.

Murthy, Vrudhula et al, Analysis of Power Spectral Densities of Electrocardiograms, Mathematical Biosciences, pp. 41-51, vol. 12 No. 1-2, Oct. 1971.

OTHER PUBLICATIONS

Nadroo, AM et al, Changes in Upper Extremity Position Cause Migration of Peripherally Inserted Central Catheters in Neonates, Pediatrics, pp. 131-136, vol. 110, Jul. 2002.

Nakatani, K et al, Accurate Placement of Central Venous Catheters—ECG-guided method vs Patient Height Method, Masui, pp. 34-38, vol. 51 No. 1, Jan. 2002.

Nazarian, GK et al, Changes in Tunneled Catheter Tip Position when a patient is Upright, J Vasc Intery Radiol, pp. 437-441, vol. 8 No. 3, May-Jun. 1997.

Neurometer® CPT, Clinical Applications. Neurotron, Inc. website: www.neurotron.com/CLINAPS.html, last accessed Oct. 23, 2006.

Neurometer® CPT, Frequently Asked Questions. Neurotron , Inc. website: www.neurotron.com/CPTFAQ/html, last accessed Oct. 23, 2006.

Neurometer® CPT, Products Page. Neurotron, Inc. website: www.neurotron.com/products.html, last accessed Oct. 23, 2006.

Neurometer® Electrodiagnostic Neuroselective Sensory Nerve Evaluation: Charts, Tables, Documents & Downloads. Neurotron, Inc. website: www.neurotron.com/downloads.html, last accessed Oct. 23, 2006.

Odd, De et al, Does Radio-opaque Contrast Improve Radiographic localisation of Percutaneous Central Venous Lines?, Arch Dis Child Fetal Neonatal Ed, pp. 41-43, vol. 89 No. 1, Jan. 2004.

Palesty, JA et al, Routine Chest Radiographs Following Central Venous Recatherization over a Wire are not Justified, Am J Surg, pp. 618-621, vol. 176 No. 6, Dec. 1998.

Paliotti, Roberta P. et al, Intravascular Doppler Technique for Monitoring Renal Venous Blood Flow in Man, J Nephrol, pp. 57-62, 2003. Parker, K.H. et al, Cardiovascular Fluid Dynamics, Department of Bioengineering, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, Cardiovascular Haemodynamics, pp. 1-28, Sep. 26, 2005.

Pawlik, et al., "Central Venous Catheter Placement: Comparison of the Intravascular Guidewire and the Fluid Column Electrocardiograms." European Journal of Anaesthesiology, vol. 41, pp. 594-599, 2004.

PCT/US2006/033079 filed Aug. 24, 2006 International Preliminary Report on Patentability dated Feb. 26, 2008.

PCT/US2006/033079 filed Aug. 24, 2006 Search Report dated Dec. 19, 2006.

PCT/US2006/033079 filed Aug. 24, 2006 Written Opinion dated Dec. 19, 2006.

PCT/US2008/060502 filed Apr. 16, 2008 International Search Report and Written Opinion dated Oct. 16, 2008.

PCT/US2008/084751 filed Nov. 25, 2008 International Preliminary Report on Patentability dated Jun. 1, 2010.

PCT/US2008/084751 filed Nov. 25, 2008 Search Report dated May 20, 2009.

20, 2003. PCT/US2008/084751 filed Nov. 25, 2008 Written Opinion dated May 20, 2009.

PCT/US2009/033116 filed Feb. 4, 2009 International Preliminary Report on Patentability dated Aug. 10, 2010.

PCT/US2009/033116 filed Feb. 4, 2009 Search Report dated Mar. 13, 2009.

PCT/US2009/033116 filed Feb. 4, 2009 Written Opinion dated Mar. 13, 2009.

PCT/US2009/041051 filed Apr. 17, 2009 Search Report dated Jul. 28, 2009.

 $\begin{array}{l} PCT/US2009/041051 \text{ filed Apr. } 17,2009 \text{ Written Opinion dated Jul. } 28,2009. \end{array}$

PCT/US2009/054687 filed Aug. 21, 2009 International Preliminary Report on Patentability dated Feb. 22, 2011.

PCT/US2009/054687 filed Aug. 21, 2009 Search Report dated Oct. 6, 2009.

PCT/US2009/054687 filed Aug. 21, 2009 Written Opinion dated Oct. 6, 2009.

"Ascension to Launch New 3D GuidanceTM Tracker at TCT 2006." Press Releases from Ascension website: www.ascension-tech.com/news/press_101106.php, last accessed Dec. 1, 2006.

Acuson—The Value of Vision, AcuNav Diagnostic Ultrasound Catheter, 2000.

Advertising flyer for GAVECELT—The Italian Group for Long Term Venous Access Devices, for program on International Meeting on PICC's, Midline Catheters and Long Term Venous Access Devices in Catholic University, Rome, Italy on Dec. 3, 4, 5, 2008.

Alexander, GD et al, The Role of Nitrous Oxide in Postoperative Nausea and Vomiting, Collection of Abstracts Presented at the International Anesthesia Research Society by various speakers, 58th Congress, Mar. 12-14, 1984, Anesthesia and Analgesia, pp. 175-284, vol. 63, 1984

Allan, P.L. et al, Role of Ultrsound in the Assessment of Chronic Venous Insufficiency, Ultrasound Quarterly, vol. 17, No. 1, pp. 3-10, 2001.

Andropoulos, et al. "A Controlled Study of the Transesophageal Echocardiography to Guide Central Venous Catheter Placement in Congetital Heart Surgery Patients." The International Anesthesia Research Society, vol. 89, pp. 65-70, 1999.

Anonymous author, Correct Catheter Placement with a low-impact, reliable and economical method, http://www.cvc-partner.com/index.cfm?103A955CC6844BF58ACFE3C9C1471959, last accessed Dec. 22, 2011.

Arai, J et al, Detection of Peripherally Inserted Central Catheter Occlusion by in-line Pressure Monitoring, Paediatr Anaesth, pp. 621-624, vol. 12 No. 7, Sep. 2002.

Arrow International, Inc., The Arrow-Johans RAECG Adapter-Making Proper Central Venous Catheter Placement More Reliable (Modle No. EG-04900), Technical Report 1987, USA.

Aslamy, et al. "MRI of Central Venous Anatomy: Implications for Central Venous Catheter Insertion." American College of Chest Physicians, Jun. 8, 2009.

 $AU\ 2006283022$ filed Aug. 24, 2006 Office Action dated Dec. 22, 2010.

AU 2008329807 exam requested Aug. 13, 2012 Examination Report No. 1 dated Feb. 15, 2013.

AU 2011289513 filed Jan. 21, 2013 Examiner's Report dated Jul. 5, 2013.

AU 2012202293 filed Apr. 19, 2012 Examination Report No. 1 dated Apr. 24, 2013.

AU 2013204243 filed Apr. 12, 2013 Examiner's Report dated Jun. 5, 2013

Aurora® System Technical Specifications, Oct. 2003.

B. Braun Website, "The Optimal Position of the Central Venous Catheter." http://www.cvcpartner.com/index. cfm18F1BDEA1310466194960A39F4E90968 (2009).

B. Braun, Certofix Central Venous Catheter for Placement Using the Seldinger Technique with Simultaneous ECG Lead Option, Feb. 2010.

Bailey, SH et al, Is Immediate Chest Radiograph Necessary after Central Venous Catheter Placement in a Surgical Intensive Care Unit?, Am J Surg, pp. 517-522, vol. 180 No. 6, Dec. 2000.

Bankier, Alexander A., Azygos Arch Cannulation by Central Venous Catheters: Radiographic Detection of Malposition and Subsequent Complications, Journal of Thoracic Imaging 12:64-69 (1997).

Barber, JM et al, A Nurse led Peripherally Inserted Central Catheter Line Insertion Service is Effective with Radiological Support, Clin Radiol, pp. 352-354, vol. 57 No. 5, May 2002.

Bard Access Systems, Sherlock Tip Location System, 5 pages, 2006. Bard Access Systems, Site Rite Vascular Access Ultrasound System, 4 pages, 2005.

Benchimol, Alberto at al, Right Atrium and Superior Vena Cava Flow Velocity in Man Measured with the Doppler-Catheter Flowmeter-Telemetry System, The Amer Journal of Medicine, pp. 303-309, vol. 48, Mar. 1970.

BioAdvance Lumen Vu, Greenhouse Fund Feb. 2004 Recipient, www.bioadvance.com http://www.bioadvance.com, 2005.

Borgobello, Bridget, App allows users to view electrocardiograms on smartphones dated Oct. 15, 2010; printed from http://www.gizmag.com/app-to-view-electrocardiograms-on-smartphones/16664/ on Feb. 4, 2011.

Buehrle, Douglas, PICC Placement in Humans using Electromagnetic Detection, http://www.corpakmedsystems.com/supplement_material/supplementpages/navigator/navarticle.html, 2008.

OTHER PUBLICATIONS

C.R. Bard, CathTrack™ Catheter Location System at www.bardaccess.com http://www.bardaccess.com>, last accessed Apr. 28, 2011.

C.R. Bard, Inc., Bard Electrophysiology Product Catalogue, Bard Catheters, pp. 74-75 (2002), USA.

CA 2,619,909 filed Aug. 24, 2006 Examiner's Report dated Oct. 26, 2012.

Cadman, A et al, To Clot or Not to Clot? That is the question in Central Venous Catheters, Clinical Radiology, pp. 349-355, vol. 59 No. 4, Apr. 2004.

Calvert, N. et al, The Effectiveness and Cost-effectiveness of Ultrasound Locating Devices for Central Venous Access: A Systematic Review and Economic Evaluation, Health Technology Assessment, vol. 7, No. 12, 2003.

Cardella, John F. et al., Interventinal Radiologic Placement of Peripherally Inserted Central Catheters, Journal of Vascular and Interventional Radiology 1993; 4:653-660.

Carlon, R et al, Secondary Migration of a Central Venous Catheter—A Case Report, Minerva Anestesiol, pp. 927-931, vol. 69 No. 12, Dec. 2003.

Caruso, LJ et al, A Better Landmark for Positioning a Central Venous Catheter, J Clinical Monitoring and Computing, pp. 331-334, vol. 17 No. 6, Aug. 2002.

Cavatorta, et al., "Central Venous Catheter Placement in Hemodialysis: Evaluation of Electrocardiography Using a Guidewire." The Journal of Vascular Access, vol. 2, pp. 45-50, 2001. Chalkiadis, GA et al, Depth of Central Venous Catheter Insertion in Adults: An Audit and Assessment of a Technique to Improve Tip Position, Anaesth Intensive Care, pp. 61-66, vol. 26 No. 1, Feb. 1998. Chamsi-Pasha, Hassan et al, Cardiac Complications of Total Parenteral Nutrition: The Role of Two-Dimensional Echocardiography in Diagnosis, Annals of the Royal College of Surgeons of England, pp. 120-123, vol. 71, 1989.

Chang, Thomas C. et al., Are Routine Ch Ladiographs Necessary After Image-Guided Placement of Internal Jugular Central Venous Access Devices?, AJR Feb. 1998;170:335-337.

Chaturvedi et al., "Catheter Malplacement During Central Venous Cannulation Through Arm Veins in Pediatric Patients." Journal of Neurosurgical Anesthesiology, vol. 15, No. 3 pp. 170-175, Jan. 2003. Chen, Zhongping et al, Optical Doppler Tomography: Imaging in vivo Blood Flow Dynamics Following Pharmacological Intervention and Photodynamic Therapy, 7 pages, vol. 67, Photochemistry and Photobiology, 1998.

Cheng, KI et al, A Novel Approach of Intravenous Electrocardiograph Technique in Correct Position the Long-Term Central Venous Catheter, Kaohsiung J Med Sci, pp. 241-247, vol. 16 No. 5, May 2000 (Abstract only).

Cheung, P., et al., The Effect of a Disposable Probe Cover on Pulse Oximetry, Anaesth Intensive Care 2002; 30: 211-214.

Chu, et al., "Accurate Central Venous Port-A Catheter Placement: Intravenous Electrocardiography and Surface Landmark Techniques Compared by Using Transesophageal Echocardiography." The International Anesthesia Research Society, vol. 98, pp. 910-914, 2004.

Claasz, Antonia et al, A Study of the Relationship of the Superior Vena Cava to the Bony Landmarks of the Sternum in the Supine Adult: Implications for Magnetic Guidance Systems, Journal, vol. 12 No. 3, JAVA, Jul. 24, 2007.

Clifford, et al. "Assessment of Hepatic Motion Secondary to Respiration for Computer Assisted Interventions." Computer Aided Surgery, vol. 7, pp. 291-299, 2002.

CN 200880012117.4 filed Apr. 16, 2008 First Office Action dated Dec. 23, 2011.

CN 200880012117.4 filed Apr. 16, 2008 Second Office Action dated Oct. 8, 2012.

CN 200880012117.4 filed Apr. 16, 2008 Third Office Action dated Apr. 27, 2013.

CN 200880125528.4 filed Nov. 25, 2008 First Office Action dated Jun. 5, 2012.

U.S. Appl. No. 13/118,138, filed May 27, 2011 Final Office Action dated Apr. 3, 2013.

U.S. Appl. No. 13/118,138, filed May 27, 2011 Non-Final Office Action dated Oct. 3, 2012.

U.S. Appl. No. 13/206,396, filed Aug. 9, 2011 Non-Final Office Action dated Feb. 27, 2014.

U.S. Appl. No. 13/213,622, filed Aug. 19, 2011 Final Office Action dated Feb. 19, 2013.

U.S. Appl. No. 13/213,622, filed Aug. 19, 2011 Non-Final Office Action dated Jul. 31, 2012.

U.S. Appl. No. 13/283,395, filed Oct. 27, 2011 Non-Final Office Action dated Apr. 23, 2013.

U.S. Appl. No. 13/336,919, filed Dec. 23, 2011 Advisory Action dated May 23, 2013.

U.S. Appl. No. 13/336,919, filed Dec. 23, 2011 Final Office Action dated Mar. 1, 2013.

U.S. Appl. No. 13/336,919, filed Dec. 23, 2011 Non-Final Office Action dated Oct. 16, 2012.

U.S. Appl. No. 13/337,987, filed Dec. 27, 2011 Non-Final Office Action dated Mar. 15, 2013.

U.S. Appl. No. 29/428,649, filed Aug. 1, 2012 Notice of Allowance dated Jul. 5, 2013.

Valdivieso, J.R. Perez, et al., Evaluation of a formula for optimal positioning of a central venous catheter inserted through the right internal jugular vein, Rev. Esp. Anestesiol. Reanim. 2003; 50: 77-79. VasoNova Inc, Vascular navigation system for accurate placement of PICCs, Start-Up Emerging Medical Ventures, pp. 44-45, vol. 14 No. 7, Jul.-Aug. 2009.

Vesely, Thomas M. et al., Central Venous Catheter Tip Position: A Continuing Controversy, J Vasc Intery Radiol 2003; 14:527-534.

VIASYS Health Care Inc. Cortrak® Fact Sheet, 2005.

VIASYS Healthcare MedSystems, Navigator® Benefits, 2008.

VIASYS Healthcare MedSystems, Navigator® Research in Cost Justification, 2008.

VIASYS MedSystems, Cortrak™ Systems Brochure, 2005.

Volcano ComboMap Features and Benefits/Technical Specifications, 2 pages, 2011.

Watters, et al. "Use of Electrocardiogram to Position Right Atrial Catheters During Surgery." Annals of Surgery, vol. 225, No. 2, pp. 165-171, 1997.

Welch Allyn Cardioperfect® PC-Based Resting ECG, 2003.

Wilson, R. G. et al, Right Atrial Electrocardiography in Placement of Central Venous Catheters, The Lancet, pp. 462-463, Feb. 27, 1988. Wong, Jeffrey J. et al., Azygos Tip Placement for Hemodialysis Catheters in Patients with Superior Vena Cava Occlusion, Cardiovasc Intervent Radiol (2006) 29:143-146.

Worley, Seth J. "Use of a Real-Time Three-Dimensional Magenetic Navigation System for Radiofrequency Ablation of Accessory Pathways." PACE, vol. 21 pp. 1636-1643, Aug. 1998.

Yilmazlar A et al, Complications of 1303 Central Venous Cannulations, J R Soc Med, pp. 319-321, vol. 90 No. 6, Jun. 1997 (Abstract only).

Yoon, SZ et al, Usefulness of the Carina as a Radiographic Landmark for Central Venous Catheter Placement in Paediatric Patients, Br J Anaesth, Jul. 2005.

Yoshida, Teruhisa et al, Detection of Concealed Left Sided Accessory Atrioventricular Pathway by P Wave Signal Averaged Electrocardiogram, J Am Coll Cardiol, pp. 55-62, 1999.

Zaaroor, et al. "Novel Magnetic Technology for Intraoperative Intracranial Frameless Navigation: In Vivo and in Vitro Results." Neurosurgery, vol. 48, No. 5. pp. 1100-1107, May 2001.

Zachariou, Zacharias et al., Intra-atrial ECG recording: a new and safe method for implantation of Broviac catheters in children, Pediatr Surg Int (1994) 9: 457-458.

CN 200880125528.4 filed Nov. 25, 2008 Second Office Action dated Mar. 6, 2013.

CN 200880125528.4 filed Nov. 25, 2008 Third Office Action dated Jul. 1, 2013.

CN 200980123021.X filed Dec. 17, 2010 First Office Action dated Nov. 19, 2012.

 $\rm CN\,200980\,144663.8$ filed May 9, 2011 First Office Action dated Dec. 5, 2012.

OTHER PUBLICATIONS

Colley, Peter S et al, ECG-Guided Placement of Sorenson CVP Catheters via Arm Veins, Anesthesia and Analgesia, pp. 953-956, vol. 63, 1984.

Collier, PE et al, Cardiac Tamponade from Central Venous Catheters, Am J Surg, pp. 212-214, vol. 176 No. 2, Aug. 1998.

ComboWire® Pressure/Flow Guide Wire Ref 9500 Series, Instructions for Use, Apr. 2011.

Corsten, et al., "Central Placement Catheter Placement Using the ECG-Guided Cavafix-Certodyn SD Catheter." Journal of Clinical Anesthesiology, vol. 6, Nov./Dec. 1994.

Cucchiara, Roy et al, Time Required and Success Rate of Percantaneous Right Atrial Catherization: Description of a Technique, Canad. Anaesth. Soc. J., pp. 572-573, vol. 27, No. 6, Nov. 1980.

Cullinane, DC et al, The Futility of Chest Roentgenograms Following Routine Central Venous Line Changes, Am J Surg, pp. 283-285, vol. 176 No. 3, Sep. 1998.

Curet, Myriam J. et al., University and Practice-based Physicians' Input on the Content of a Surgical Curriculum, The American Journal of Surgery® vol. 178 Jul. 1999, 78-84.

David, et al., "Is ECG-Guidance a Helpful Method to Correctly Position a Central Venous Catheter During Prehospital Emergency Care?" ACTA Anaesthesiologica Scandinavica, vol. 49, pp. 1010-1014, 2005.

DELTEC Cath-Finder® Tracking System Operation Manual, 1994. Egelhof, Petra, Effects of Somatostatin on Portal Blood Flow and Portal Vein Pressure in Patients with Portal Hypertension due to Liver Cirrhosis Invasive Monitoring during TIPSS Procedures, Dissertation submitted to: Technical University of Munich, Faculty of Medicine, May 13, 2002; Date of examination: Feb. 26, 2003.

Engelhardt, W et al, ECG-Controlled Placement of Central Venous Catheters in Patients with Atrial Fibrallation, Anaesthesist, pp. 476-479, vol. 38 No. 9, Sep. 1989 (Abstract only).

EP 08855396.1 filed Jun. 15, 2010 European Search Report dated Jul. 31, 2012.

EP 08855396.1 filed Jun. 15, 2010 Intent to Grant dated Jul. 5, 2013. EP 09707467.8 supplemental European search report dated Jun. 18, 2013.

EP 09808901.4 filed Aug. 21, 2009 European Search Report dated May 23, 2012.

EP 09808901.4 filed Aug. 21, 2009 Examination Report dated May 10, 2013.

EP 09813632.8 filed Apr. 5, 2011 European Search Report dated Jul. 4, 2012.

EP 09813632.8 filed Apr. 5, 2011 Office Action dated Apr. 30, 2013. EP 12177438.4 filed Jul. 23, 2012 European Search Report dated Dec. 4, 2012.

 $\rm EP\,12177438.4\,filed\,Jul.\,23,2012$ extended European Search Report dated Mar. 25, 2013.

Fearon, William F et al, Evaluating Intermediate Coronary Lesions in the Cardiac Catheterization Laboratory, vol. 4, No. 1, 7 pages, Reviews in Cardiovascular Medicine, 2003.

Felleiter P et al, Use of Electrocardiographic Placement Control of Central Venous Catheters in Austria, Acta Med Austriaca, pp. 109-113, vol. 26 No. 3, 1999 (Abstract only).

Forauer, AR et al, Change in Peripherally Inserted Central Catheter Tip Location with Abduction and Adduction of the Upper Extremity, J Vasc Intery Radiol, pp. 1315-1318, vol. 11 No. 10, Nov.-Dec. 2000. Frassinelli, P et al, Utility of Chest Radiographs after Guidewire Exchanges of Central Venous Catheters, Crit Care Med, pp. 611-615, vol. 26 No. 3, Mar. 1998.

Frazin L et al, A Doppler Guided Retrograde Catheterization System, Cathet. Cardiovasc Diagn, pp. 41-50, May 1992.

French, PJ et al, Sensors for Catheter Applications, Sensors Update, vol. 13 Issue 1 pp. 107-153, Dec. 2003.

GB Application 0800474.9 filed Aug. 24, 2006 Office Action dated Aug. 9, 2010.

GB Application 0800474.9 filed Aug. 24, 2006 Office Action dated Mar. 17, 2010.

Gebauer, B et al, Ultrasound and Fluoroscopy-guided Implantation of Peripherally Inserted Central Venous Catheters (PICCs), ROFO, pp. 386-391, vol. 176 No. 3, Mar. 2004 (Abstract only).

Gebhard, et al., "The accuracy of Electrocardiogram-Controlled Central Line Placement." The International Anesthesia Research Society, vol. 104, No. 1 Jan. 2007.

Gjendemsjo, Anders, et al., Energy and Power, The Connexions Project, Version 1.2, Feb. 20, 2004.

Gladwin, MT et al, Cannulation of the Internal Jugular Vein: is postpocedural chest radiography always necessary?, Crit Care Med, 33 pages, Oct. 2000.

Gonzales, et al. "Peripherally Inserted Central Catheter Placement in Swine Using Magnet Detection." Journal of Intravenous Nursing, vol. 22, No. 3, May/Jun. 1999.

Greenall, M.J. et al, Cardiac Tamponade and Central Venous Catheters, British Medical Journal, pp. 595-597, Jun. 14, 1975.

Guillory, "Basic Principles of Technologies for Catheter Localization." C.R. Bard internal paper, Oct. 20, 2004.

Guth, AA, Routine Chest X-rays after Insertion of Implantable Long-Term Venous Catheters: Necessary or Not?, Am Surg, pp. 26-29, vol. 67 No. 1, Jan. 2001 (Abstract only).

Hill, Bradley et al, Abstract of article discussing VasaNova VPS as guide for placement of PICCs. 2009.

Hill, Bradley, Identifying the Caval-Atrial Junction Using Smart-Catheter Technology presentation, 22nd Annual Scientific Meeting of the AVA in Savannah, Georgia, Sep. 13, 2008.

Hoffman, Thomas et al, Simultaneous Measurement of Pulmonary Venous Flow by Intravascular Catheter Doppler Velocimetry and Transesophageal Doppler Echocardiography: Relation to Left Atrial Pressure and Left Atrial and Left Ventricular Function, pp. 239-249, J Am Coll Cardiol, Jul. 1995.

Hoffmann, et al. "New Procedure in Transesophageal Echocardiography: Multiplane Transesophageal Echocardiography and Transesophageal Stress Echocardiography." Herz, vol. 18, No. 5, pp. 269-277, Oct. 1993.

Iacopino, Domenico Gerardo et al, Intraoperative Microvascular Doppler Monitoring of Blood Flow within a Spinal Dural Arteriovenous Fistula: A Precious Surgical Tool, vol. 10, 5 pages, Neurosurg. Focus, Feb. 2001.

Joosting, Jean-Pierre, "Dual-interface RFID-compatible EEPROM enables remote access to electronic device parameters," EE Times, Mar. 8, 2010.

JP 2008-528151 filed Aug. 24, 2006 Notice of Grant dated May 6, 2012

JP 2010-504220 filed Sep. 3, 2009 Final Office Action dated Apr. 18, 2013.

JP 2010-504220 filed Sep. 3, 2009 Office Action dated May 21, 2012. Kim, Ko et al, Positioning Internal Jugular Venous Catheters using the Right Third Intercostal Space in Children, Acta Anaesthesiol Scand, pp. 1284-1286, vol. 47 No. 10, Nov. 2003.

Schummer, W et al, ECG-guided Central Venous Catheter Positioning: Does it detect the Pericardial Reflection rather than the Right Atrium?, Eur J Anaesthesiol, pp. 600-605, vol. 21 No. 8, Aug. 2004 (Abstract only).

Schummer, W et al, Intra-Atrial ECG is not a Reliable Method for Positioning Left Internal Jugular Vein Catheters, Br J Anaesth, pp. 481-486, vol. 91 No. 4, Oct. 2003.

Schummer, W, Central Venous Catheter—The Inability of "Intra-Atrial ECG" to prove Adequate Positioning, Br J Anaesth, pp. 193-198, vol. 93 No. 2, Aug. 2004.

Schuster, M. et al., The carina as a landmark in central venous catheter placement, British Journal of Anaesthesia 85 (2): 192-4 (2000).

Siela, Debra, Using Chest Radiography in the Intensive Care Unit, Crit Care Nurse Aug. 1, 2002 vol. 22 No. 4, pp. 18-27.

Silindir, M. et al., "Sterilization Methods and the Comparison of E-Beam Sterilization with Gamma Radiation Sterilization," FABAD J. Pharm. Sci., 34, 43-53, 2009.

Simon, et al., "Central Venous Catheter Placement in Children: Evaluation of Electrocardiography Using J-Wire." Paediatric Anaesthesia vol. 9, pp. 501-504, 1999.

OTHER PUBLICATIONS

Smith, Brigham, et al., Intravenous electrocardiographic guidance for placement of peripherally inserted central catheters, Journal of Electrocardiology 43 (2010) 274-278.

Stark, DD et al, Radiographic Assessment of Venous Catheter Position in Children: Value of the Lateral View, Pediatric Radiology, pp. 76-80, vol. 14 No. 2, 1984.

Starkhammar et al. "Cath-Finder Catheter Tracking System: A New Device for Positioning of Central Venous Catheters. Early Experience from Implantation of Brachial portal Systems." Acta Anaesthesiol Scandinavia, vol. 34, No. 4 pp. 296-300, May 1990.

Starkhammer, H et al, Central Venous Catheter Placement using Electromagnetic Position Sensing: A Clinical Evaluation, Biomed. Instrum Technol, vol. 30 No. 2, pp. 164-170; Mar.-Apr. 1996.

Starr, David S et al, EKG Guided Placement of Subclavian CVP Catheters Using J-Wire, pp. 673-676, Ann. Surg, Dec. 1986.

Stas, M et al, Peroperative Intravasal Electrographic Control of Catheter Tip Position in Access Ports Placed by Venous Cut-Down Technique, EJSO, pp. 316-320, vol. 27, 2001.

Stereotaxis Magetic Navigation System with Navigant™ User Interface, 2005 Brochure.

Stereotaxis, Expanding the Possibilites of Interventional Medicine: Remote Navigation and Automation, pp. 1-8, Apr. 2011.

Tepa® Health Innovation PC based ECG System Introduction and Technical Specifications, EKG Master USB, 2 pages, Nov. 2003.

The FloWire Doppler Guide Wire located http://www.volcanocorp.com/products/flowire-doppler-guide-wire.php, 2011.

Traxal Technologies, Tracking Technology website overview: www. traxal.com/rd/rd_classroom_trackingtechnology.htm, last accessed Dec. 1, 2006.

UAB Health Systems, Arrhythmias, retrieved from http://www.health,uab.edu/14564/ on Nov. 15, 2007, 12 pages.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Advisory Action dated Jun. 22, 2009.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Appeal Board Decision dated Sep. 17, 2012.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Final Office Action dated Apr. 8, 2010.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Final Office Action dated Jan. 30, 2009.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Non-Final Office Action dated Mar. 28, 2013.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Non-Final Office Action dated Sep. 25, 2009.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Notice of Allowance dated Dec. 3, 2012.

U.S. Appl. No. 11/552,094, filed Oct. 23, 2006 Notice of Allowability dated Apr. 2, 2010.

U.S. Appl. No. 11/552,094, filed Oct. 23, 2006 Non-Final Office Action dated Apr. 27, 2009.

U.S. Appl. No. 11/552,094, filed Oct. 23, 2006 Notice of Allowance dated May 20, 2010.

U.S. Appl. No. 12/104,253, filed Apr. 16, 2008 Final Office Action dated Jul. 27, 2011.

U.S. Appl. No. 12/104,253, filed Apr. 16, 2008 Non-Final Office Action dated Nov. 29, 2010.

U.S. Appl. No. 12/323,273, filed Nov. 25, 2008 Non-Final Office Action dated Jun. 8, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Final Office Action dated Feb. 23, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Notice of Allowance dated Oct. 5, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Notice of Panel Decision dated Aug. 1, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Non-Final Office Action dated Jul. 20, 2011.

U.S. Appl. No. 12/426,175, filed Apr. 17, 2009 Non-Final Office Action dated Dec. 3, 2012.

U.S. Appl. No. 12/427,244, filed Apr. 21, 2009 Non-Final Office Action dated Jan. 19, 2012.

U.S. Appl. No. 12/545,762, filed Aug. 21, 2009 Final Office Action dated Mar. 7, 2013.

U.S. Appl. No. 12/545,762, filed Aug. 21, 2009 Non-Final Office Action dated Aug. 1, 2012.

U.S. Appl. No. 12/557,401, filed Sep. 10, 2009 Non-Final Office Action dated Apr. 24, 2012.

U.S. Appl. No. 12/575,456, filed Oct. 7, 2009 Non-Final Office Action dated Oct. 5, 2012.

U.S. Appl. No. 12/715,556, filed Mar. 2, 2010 Non-Final Office Action dated Sep. 13, 2012.

U.S. Appl. No. 12/854,083, filed Aug. 10, 2010 Non-Final Office

Action dated Jan. 29, 2013. U.S. Appl. No. 12/878,915, filed Sep. 9, 2010 Final Office Action

dated Sep. 26, 2012. U.S. Appl. No. 12/878,915, filed Sep. 9, 2010 Non-Final Office

Action dated Mar. 15, 2012. U.S. Appl. No. 12/878,915, filed Sep. 9, 2010 Notice of Allowance

dated Jan. 8, 2013. U.S. Appl. No. 12/900,750, filed Oct. 8, 2010 Final Office Action

dated Dec. 3, 2013. U.S. Appl. No. 12/900,750, filed Oct. 8, 2010 Non-Final Office

Action dated Apr. 10, 2014. U.S. Appl. No. 12/900,750, filed Oct. 8, 2010 Non-Final Office

Action dated Jun. 3, 2013. JP 2013-524183 filed Feb. 8, 2015 First Office Action dated Jun. 24,

2015. U.S. Appl. No. 13/206,396, filed Aug. 9, 2011, Final Office Action

U.S. Appl. No. 13/206,396, filed Aug. 9, 2011, Final Office Action dated Jun. 10, 2015.

^{*} cited by examiner





FIG. 1






FIG. 2B




FIG. 2C





FIG. 3








FIG. 4C









FIG. 7



RUGGEDIZED ULTRASOUND HYDROGEL INSERT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/563,382, filed Nov. 23, 2011, and titled "Ruggedized Ultrasound Hydrogel Insert," and U.S. Provisional Application No. 61/556,626, filed Nov. 7, 2011, and titled, "Systems and Methods for Ultrasound-Based Pneumothorax," each of which is incorporated herein by reference in its entirety.

BRIEF SUMMARY

Briefly summarized, embodiments of the present invention are directed to a ruggedized hydrogel product that is formulated to withstand the effects of high-energy sterilization procedures, such as gamma beam and electron beam sterilization, without significant structural degradation. This enables the hydrogel product to be suitable for use in medical applications where sterile components are required.

In one embodiment a ruggedized hydrogel product is disclosed and comprises a gel component, water for hydrating the gel component, and at least one free radical absorber component that is capable of absorbing free radicals produced when the hydrogel product is sterilized via high-energy sterilization procedures. The free radical absorber component in one embodiment includes potassium metabisulfite and ascorbic acid.

The ruggedized hydrogel product can be included with an ultrasound probe to provide an acoustically transparent interface between the probe and the skin of a patient. In one embodiment, the hydrogel is configured as an insert included with a cap that can be removably attached to the probe. In another embodiment, the hydrogel is configured as a slab that is attached to the bottom of a pancake probe. In addition, other configurations can also be employed.

These and other features of embodiments of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of embodiments of the invention as set forth hereinafter.

BRIEF DESCRIPTION OF THE DRAWINGS

A more particular description of the present disclosure will 50 be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be 55 described and explained with additional specificity and detail through the use of the accompanying drawings in which:

FIG. 1 is a perspective view of a cap for an ultrasound probe including a ruggedized hydrogel insert according to one embodiment;

FIGS. 2A-2C are various views of a tray for housing the cap of FIG. 1 according to one embodiment;

FIG. 3 shows the cap of FIG. 1 disposed in the tray of FIGS. 2A-2C according to one embodiment;

FIGS. 4A and 4B are exploded front and side perspective 65 views of an ultrasound probe including the cap of FIG. 1 according to one embodiment;

2

FIG. 4C is an assembled front perspective view of the ultrasound probe and cap of FIGS. 4A and 4B according to one embodiment:

FIG. 5 shows an ultrasound system including a probe for use with a patient according to one embodiment;

FIGS. 6A and 6B are various views of an ultrasound probe including a ruggedized hydrogel product according to one embodiment;

FIG. 7 is a top view of an ultrasound probe including a ruggedized hydrogel product according to one embodiment; and

FIG. **8** is a flow diagram showing preparation and dispensing of a ruggedized hydrogel product according to one embodiment.

DETAILED DESCRIPTION OF SELECTED EMBODIMENTS

Reference will now be made to figures wherein like structures will be provided with like reference designations. It is understood that the drawings are diagrammatic and schematic representations of exemplary embodiments of the present invention, and are neither limiting nor necessarily drawn to scale.

For clarity it is to be understood that the word "proximal" refers to a direction relatively closer to a clinician using the device to be described herein, while the word "distal" refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Also, the words "including," "has," and "having," as used herein, including the claims, shall have the same meaning as the word "comprising."

Embodiments of the present invention are generally directed to a ruggedized hydrogel product that is formulated to withstand the effects of high-energy sterilization procedures, such as gamma beam and electron beam ("e-beam") sterilization, without significant structural degradation. This enables the hydrogel product to be suitable for use in medical applications where sterile components are required.

For example, the ruggedized hydrogel product can be included in one embodiment for use with an ultrasound probe. Particularly, the hydrogel product in one embodiment is positioned between a head portion of the probe and the patient's skin so as to act as an acoustically coupling interface during use of the probe in imaging subcutaneous tissue of the patient. This enables ultrasound signals emitted and received by the probe head to be efficiently transmitted between the head and the patient's body through the hydrogel, thus improving the quality of images produced by the ultrasound signals.

In addition, the hydrogel includes a substantial amount of water, which is exuded therefrom during use, thus providing a low friction interface that enables smooth sliding movement of the probe atop the skin. The relatively high water content of the hydrogel also mimics the composition of tissue in the patient's body, thus providing a relatively uniform medium for the transmission of ultrasound signals into and out of the body. Moreover, the hydrogel as disclosed herein is solid but compliant so as to conform to variations in the skin surface, thus enhancing the ability to maintain acoustic coupling between the probe head and the patient's body when the probe is slid over the patient's skin.

As mentioned above, the hydrogel product is both biocompatible and sterilizable so as to be usable in standard clinical environments. In particular, the hydrogel formulations disclosed herein can be subjected to standard sterilizing procedures, such as gamma beam and electron beam sterilization, without liquefying or otherwise physically degrading. This enables the hydrogel to successfully and safely undergo sterilization procedures together with other components to be sterilized, such as within a kit for instance, which increases manufacturing efficiency. In addition, the hydrogel can be configured to withstand other forms of sterilization/sterilizing materials, including ultraviolet light, hydrogen peroxide, ozone, and corona discharge treatment, in one embodiment. As used herein, "hydrogel" is understood to include a polymer network dispersed in water, often exhibited as a semisolid gel.

Reference is made to FIG. 1, which depicts a cap 10 for use with an ultrasound probe, such as the probe 30 shown in FIGS. 4A-4C, according to one embodiment. The cap 10 is 20 configured to operably attach to the probe 30 in a snap-fit or other suitable arrangement so as to cover at least a portion of a head portion 32 of the probe. Further details regarding the ultrasound probe 30 are given further below.

A hydrogel insert 12 including a hydrogel product config- 25 ured in accordance with one embodiment is included with the cap 10. As shown in FIG. 1, the insert 12 is disposed in an opening 14 defined in the cap 10 so as to be secured in the configuration shown. The distal end of the insert 12 defines a concave shape to act, in one embodiment, as a standoff component for providing a physical separation between the ultrasound probe 30 (FIGS. 4A-4C) and the patient's skin, thus preventing compression of superficial veins beneath the skin and therefore enabling suitable imaging thereof. In the present embodiment, a fixture 16 is included on the cap 10 for receipt of a needle guide to help guide a needle into the patient after a suitable vessel has been found via ultrasound imaging. Further details regarding the cap and needle guide can be found in U.S. Publication No. 2011/0313293, filed Aug. 9, 40 2011, and U.S. Publication No. 2012/0165679, filed Dec. 22, 2011, and titled "Selectable Angle Needle Guide", each of which is incorporated herein by reference in its entirety. It should be noted that the discussion herein concerning the hydrogel component and its use with an ultrasound probe is 45 merely an example of one implementation thereof and should not be considered limiting of the range of possible uses for the hydrogel product.

FIGS. 2A-2C show a tray 20 that serves as a mold in the present embodiment for forming the hydrogel insert 12 of 50 FIG. 1, as will be described. The tray 20 includes a suitable material such as a thermoplastic and defines a cavity 22 for receiving various components therein. Specifically, a cap cavity portion 24 is defined in the cavity 22 and is shaped to removably receive therein the cap 10 of FIG. 1. A convexly-shaped hydrogel insert cavity portion 26 is defined within the cap cavity portion 24 and is shaped to provide a mold surface and volume for defining the hydrogel insert 12 when the insert is manufactured, as will be described further below. Also included is a cavity area 28 adjacent the cap cavity portion 24 to provide a space where a needle guide can be disposed if attached to the cap.

FIG. 3 shows the cavity 22 of the tray 20 with the cap 10 disposed in the cap cavity portion 22 thereof. With the cap 10 so positioned a volume is defined, as mentioned, proximate 65 the distal end of the cap 10 and the hydrogel insert cavity portion 26 in which the hydrogel product can be disposed and

4

cured, as discussed further below, in order to form the hydrogel insert 12 in an attached configuration with the cap, as seen in FIG. 1.

FIGS. 4A-4C show the manner of attachment of the cap 10 to the head portion 32 of the ultrasound probe 30. Surface features on the cap 10 and the head 32 are included to enable the cap to be removably attached to the head in a friction fit arrangement, though other attachment schemes may also be used. This places the hydrogel component of the insert 12 at the distal end of the probe 30 to provide an ultrasonically transparent interface between transducer elements disposed in the probe head 32 and the patient's skin. Again, the probe, the cap, and the manner in which the hydrogel component is configured and used can vary from what is shown and described herein.

As mentioned, the hydrogel product of the insert 12 of the cap 10 is used in medical applications to assist with ultrasonic imaging procedures, such as imaging a subcutaneous vessel in preparation for insertion of a catheter, needle, or other medical device therein. As such, the cap 10 and accompanying hydrogel insert must often be sterilized prior to use so as to prevent transmission of microbes, diseases, viruses, bacteria, and so forth. In the present embodiment the hydrogel product is formulated so as to withstand high-energy sterilization procedures that are typically used to sterilize medical devices and equipment.

Specifically, in one embodiment the hydrogel product from which the insert 12 is made includes a ruggedized formulation to provide the desirable qualities discussed above, including the ability to sterilize the hydrogel insert via gamma beam or electron beam sterilization procedures without causing physical degradation of the hydrogel. In one embodiment a hydrogel product is disclosed that includes various components, namely: a gel component to provide the gel structure itself, and water to hydrate the initially dry gel component. In accordance with the present embodiment, one or more free radical absorber components are also included in the composition to absorb free radicals that are produced in the hydrogel as a result of the high-energy sterilization process. Left unchecked, the free radicals cause undesired degradation and liquefying of the hydrogel, rendering it useless for the intended ultrasound-related uses discussed above. By including these absorbers in the hydrogel component, the free radicals are neutralized and are thus unable to cause hydrogel degradation.

According to one embodiment, non-limiting examples of free radical absorbers that can be utilized in the hydrogel of the insert 118 or other implementation include: glutathione, potassium metabisulfite, potassium disulfite, sodium formate, potassium formate, L-ascorbic acid, sodium citrate monobasic, L-glutamic acid monosodium salt, L-glutamic acid, catechin, organic compound-containing thiol, potassium iodide, vitamin E, cysteine, and other suitable absorbers including antioxidants employed in the food and cosmetics industry. Other salt forms of the above compounds can also be employed as suitable free radical absorbers. For instance potassium formate, a salt compound related to sodium formate, can be also be employed as a free radical absorber. In addition to the gel component and free radical absorber components, and water, other additive components can be included, including mixing aids, preservatives, etc.

In light of the above, in one example embodiment a hydrogel product includes the following composition:

Category	Component	Quantity (percentage by weight, per each hydrogel unit)
Gel Component	Carrageenan Gum & Konjac Gum	About 2.09%
Free Radical Absorber	Potassium Metabisulfite	About 1.86%
Free Radical Absorber	Ascorbic Acid	About 0.025%
Additive Hydrating Medium	Isopropyl Alcohol Deionized Water	About 0.95% About 95.07%

As seen in Table 1, the hydrogel component according to the present embodiment includes a gel component, two free 15 radical absorber components, an additive, and water as a hydrating medium. The gel component in the present embodiment includes a hydrogel powder product, Stabilizer VPB-1, sold under the trademark COYOTE and manufactured by Gum Technology of Tucson, Ariz. Comparable products are attainable from other sources. The Stabilizer VPB-1 powder gel component includes both carrageenan gum and konjac gum and provides the base for the hydrogel product. In one embodiment, the Stabilizer VPB-1 powder gel component includes a particle size of 90% minimum passage through a 25 U.S. Standard 40 mesh sieve and can include potassium chloride and/or calcium chloride to provide standardization thereof

The free radical absorbers of Table 1 include potassium metabisulfite (also known as potassium disulfite) and ascorbic acid, otherwise known as vitamin C. Each of these provides stability to the hydrogel component in absorbing free radicals created in the hydrogel during subsequent high-energy sterilization procedures. In the present embodiment, the potassium metabisulfite is initially in powder form and possesses a purity of greater than or equal to about 95%. The ascorbic acid is also initially in powder form and possesses a purity equal to or exceeding about 99%. In one embodiment, the above components can generally meet food or nutriceutical grade for use in the present hydrogel product formulation. It is appreciated that the term "powder" herein can include various physical forms including particulate, granular, crystalline, crushed, etc.

The additive isopropyl alcohol ("IPA") in the present embodiment is of USP grade at a purity of equal to or exceeding 99%. The IPA aides in the dissolving and/or mixing of the other ingredients during hydrogel manufacture and also assists in neutralizing the scent of the hydrogel created by the free radical absorbers components. The water serves as the hydrating medium for the hydrogel product and subsequently provides the acoustic transparency necessary for the hydrogel product. In the present embodiment, deionized water is employed to provide an acceptable purity level. However, in other embodiments other forms of water with a low bioburden or contaminant level can be employed, including sterile water, distilled water, filtered water, etc. Note also that the relative concentrations or inclusion of the various components can be varied from what is shown herein.

FIG. **8** provides a flow diagram **100** describing various stages of the preparation of the hydrogel product described 60 herein. Though directed toward preparation of the hydrogel product having the formulation depicted in Table 1 above, the flow diagram **100** can also be applied to other possible hydrogel formulations, including those additionally described herein. At stage **102** the dry powder gel component, i.e., the 65 Stabilizer VPB-1 powder in the present embodiment, can be subjected to a pre-treatment heating process in order to

6

reduce or eliminate any bio-burden, or presence of undesired biological entities (microbes, insects, etc.) In the present embodiment, the gel component is subjected to oven heating at about 120 degrees Celsius for about 4 to 5 hours.

At stage 106, a measured amount the pre-treated gel component is combined with measured amounts of the powder forms of the free radical absorber components 104, i.e., the potassium metabisulfite and ascorbic acid in the present embodiment. In one embodiment, combining of these components is achieved via dry-mixing. In another embodiment, the powder components are merely combined without active mixing.

At stage 108, the combined powder from stage 106 is mixed into a vessel with measured amounts of deionized water, represented at block 110, and IPA, represented at block 112. In the present embodiment, the liquid IPA is added to the deionized water already present in the vessel before the dry-mixed powder is introduced into the vessel. In another embodiment, the IPA and water can be added at the same time. A mechanical mixer can be used and the dry-mixed powder added slowly to the deionized water/IPA mixture to ensure dispersion and dissolving of the powder. The hydrated mixture ("hydrogel solution") is mixed for about two minutes after all the components have been added, in the present embodiment.

At stage 114, the hydrogel solution is subjected to a vacuum in order to reduce or eliminate any air bubbles in the mixture. In the present embodiment, the vessel used at stage 108 is a pressure vessel suitable for providing a vacuum so the hydrogel solution need not be transferred to another container. The vacuum is applied to the hydrogel solution a minimum of 10 minutes in the present embodiment so that all or most air bubbles trapped in the solution are released. The hydrogel solution can then be inspected to ensure it is smooth and substantially bubble-free. If not, the vacuum process can be repeated.

At stage 116 the hydrogel solution is heated to a temperature of about 85-90 degrees Celsius to keep it flowable in preparation for dispensing it at stage 118 and completing preparation of the hydrogel product. Of course, the heating temperature and other details of the procedure described herein can be varied in accordance with alterations in the hydrogel formula, intended use, etc., as appreciated by one skilled in the art. In the present embodiment, the hydrogel solution is loaded into a suitable pumping/dispensing device. Note that the dispensing device can also provide the needed heating of the solution shown at stage 116.

With respect to dispensing the hydrogel solution of stage 118, in one embodiment the solution is dispensed into a portion of the tray 20 shown and described in connection with FIGS. 2A-3. In particular, the hydrogel solution can be dispensed into the volume defined by the hydrogel insert cavity portion 26 when the cap 10 is disposed within the tray 20. As mentioned, the portion of the tray 20 that defines the hydrogel insert cavity portion 26 is shaped so as to impart the desired shape of the hydrogel insert 12 (see FIG. 1) when the hydrogel solution solidifies after dispensing.

In the present embodiment, the dispensing stage 118 includes placing the cap 10 (FIG. 1) in the cap cavity portion 24 of the cavity 22 of the tray 20 as shown in FIG. 3. In one embodiment a needle guide can be attached to the cap 10 prior to placing it in the tray 20; if so, the needle guide is disposed in the cavity area 28 of the tray cavity 22 when the cap is placed in the tray.

Once the cap is disposed in the tray, the cap 10 can be treated with a corona discharge treatment process to improve

cap surface characteristics for receipt of the hydrogel solution that will solidify to form the hydrogel insert 12, FIG. 1.

After the corona discharge treatment the hydrogel solution, which is heated as previously described to maintain flowability, is dispensed from a suitable dispenser into the hydrogel insert cavity portion 26 of the tray cavity 22 in sufficient quantity to fill the cavity portion and backfill into the cap 10 via the opening 14 thereof a limited amount. Inspection after filling may indicate if air bubbles are present, the fill was insufficient or non-uniform or messy, etc. such that corrective measures may be taken.

After dispensing of the hydrogel solution into the cap 10 within the tray 20, the tray is left flat for at least 30 seconds in one embodiment to ensure that the hydrogel solution properly cures and solidifies into the hydrogel insert 12 (FIG. 1). As a portion of the hydrogel solution solidifies within the volume defined by the cap 10, attachment between the hydrogel and the cap is achieved. Note that the above-described procedures can be performed for each cap individually or in a batch process where multiple caps are filled with hydrogel solution. Note also that this is but one possible use for the ruggedized hydrogel; other hydrogel applications can also benefit from the principles described herein.

After curing of the hydrogel solution, the cap 10 and newly-formed hydrogel insert 12 can be sterilized by high-energy sterilization procedures without being removed from the tray 20. As described, because of its formulation the hydrogel product can withstand such high-energy sterilization without undesirably degrading and liquefying. In one example, the hydrogel product was exposed to about 30 kGy of ionizing radiation (gamma beam) sterilization without significant resultant hydrogel degradation.

Once sterilization is complete, the tray 20, including the cap 10 and attached hydrogel insert 12 disposed therein, can be packaged, stored, used, etc. For instance, the cap 10 in one embodiment may be attached to and used with an ultrasound probe, such as the probe 30 shown in FIG. 4C.

Below are various examples of preparations of a hydrogel product in accordance with embodiments of the present disclosure.

EXAMPLE 1

A hydrogel product was prepared by first pre-treating about 100 grams of Gum Tech Stabilizer VPB-1 powder in an oven for about four hours at about 120 degrees Celsius. About 86.0 to about 89.9 grams of the pre-treated Stabilizer VPB-1 45 powder was then combined with about 75.7 to about 80.0 grams of potassium metabisulfite powder and about 1.01 to about 1.06 grams of ascorbic acid powder to form a hydrogel powder. The hydrogel powder was then mixed into an aqueous solution of about 4,000 ml of deionized water and about 50 40 ml of isopropyl alcohol for approximately two minutes after all of the hydrogel powder had been added to the aqueous solution. A vacuum cycle of about 10 minutes was then applied to the resultant hydrogel solution to remove any air bubbles. The hydrogel solution was then heated to a temperature of from about 85 to about 90 degrees Celsius and dispensed to a tray mold. The molded hydrogel solution was allowed to cure for about 30 seconds to form a completed hydrogel product. Note that the purities and other characteristics of the components of the hydrogel solution of the 60 present example are similar to those described in the above discussion relating to FIG. 8.

EXAMPLE 2

A hydrogel product was prepared by first combining dry powders of the following components in the specified con8

centrations (percentages are w/w-by weight) to form a hydrogel powder: gel component: kappa-carrageenan gum- about 0.7%; iota-carrageenan gum- about 0.3%; konjac gum- about 0.5%; potassium chloride- about 0.010% (about 8 milliMolar ("mM")); free radical absorber components: L-ascorbic acidabout 2.5% (about 140 mM); potassium metabisulfite- about 1.33% (about 50 mM); preservatives: propyl 4-hydroxybenzoate- about 0.18% (about 1.0 mM); methyl 4-hydroxybenzoate- about 0.05% (about 0.4 mM). The hydrogel powder was then mixed into an aqueous solution to form a hydrogel solution. The aqueous solution included isopropyl alcohol comprising about 4% (about 500 mM) of the total hydrogel solution and deionized water comprising about 90.66% of the total hydrogel solution. The hydrogel solution was mixed for at least two minutes after all of the hydrogel powder had been added to the aqueous solution. The hydrogel solution was then heated and dispensed to a mold. The molded hydrogel solution was allowed to cure to form a completed hydrogel product.

EXAMPLE 3

A hydrogel product was prepared by first combining dry powders of the following components in the specified concentrations (percentages are w/w-by weight) to form a hydrogel powder: gel component: kappa-carrageenan gum- about 0.7%; iota-carrageenan gum- about 0.3%; konjac gum- about 0.5%; potassium chloride- about 0.010% (about 8 milliMolar ("mM")); free radical absorber components: L-ascorbic acidabout 2.5% (about 140 mM); glutathione- about 1.2% (about 40 mM); preservatives: propyl 4-hydroxybenzoate- about 0.18% (about 1.0 mM); methyl 4-hydroxybenzoate- about 0.05% (about 0.4 mM). The hydrogel powder was then mixed into an aqueous solution to form a hydrogel solution. The aqueous solution included isopropyl alcohol comprising about 4% (about 500 mM) of the total hydrogel solution and deionized water comprising about 90.56% of the total hydrogel solution. The hydrogel solution was mixed for at least two minutes after all of the hydrogel powder had been added to the aqueous solution. The hydrogel solution was then heated and dispensed to a mold. The molded hydrogel solution was allowed to cure to form a completed hydrogel product.

EXAMPLE 4

A hydrogel product was prepared by first combining dry powders of the following components in the specified concentrations (percentages are w/w-by weight) to form a hydrogel powder: gel component: kappa-carrageenan gum- about 0.7%; iota- carrageenan gum- about 0.3%; konjac gum- about 0.5%; potassium chloride- about 0.010% (about 8 milliMolar ("mM")); free radical absorber components: L-ascorbic acidabout 2.5% (about 140 mM); sodium formate- about 2.0% (about 300 mM); preservatives: propyl 4-hydroxybenzoateabout 0.18% (about 1.0 mM); methyl 4- hydroxybenzoateabout 0.05% (about 0.4 mM). The hydrogel powder was then mixed into an aqueous solution to form a hydrogel solution. The aqueous solution included isopropyl alcohol comprising about 4% (about 500 mM) of the total hydrogel solution and deionized water comprising about 89.76% of the total hydrogel solution. The hydrogel solution was mixed for at least two minutes after all of the hydrogel powder had been added to the aqueous solution. The hydrogel solution was then heated and dispensed to a mold. The molded hydrogel solution was allowed to cure to form a completed hydrogel product.

It is appreciated that in other embodiments the formulations identified in Examples 2-4, can omit the preservatives

propyl 4-hydroxybenzoate and methyl 4-hydroxybenzoate from the hydrogel product formulation. In another embodiment, the free radical absorber ascorbic acid can be omitted from the hydrogel product formulation. In yet another embodiment, a suitable antibacterial/antimicrobial component could be added to the hydrogel formulation. IPA can be varied in concentration, such as from about one to about five percent by weight in one embodiment, or omitted from the composition in one embodiment. Indeed, if IPA is omitted from the hydrogel formulation, a small amount could still be added to an external portion of the hydrogel product postmanufacture so as to assist in masking any unpleasant smell of the hydrogel. Other aromatic or fragrant substances can optionally be used to mask the hydrogel odor. It is also appreciated that other gel components in addition to those listed herein can be employed, including polysaccharide-based gel components, for instance.

In yet another embodiment, it is appreciated that the hydrogel product can include a component to render the hydrogel 20 bacteriostatic. In such a case, it may be chosen to not sterilize the hydrogel product, but rather rely on its bacteriostatic qualities. In one embodiment, a suitable substance, such as chlorhexadine, can be added to the hydrogel component to render it bacteriostatic. In this instance, the IPA could be 25 included or omitted from the hydrogel formulation.

Reference is now made to FIG. 5 in describing one possible implementation of a ruggedized hydrogel product according to one embodiment. A patient 50 is shown undergoing an ultrasound imaging procedure with the use of an ultrasound 30 imaging system 60, which includes a console 62 housing a display 64. An ultrasound probe 70, configured in accordance with one embodiment, is operably connected to the console 62 via a cable 72 or other suitable connective scheme and is positioned atop a portion of the patient's chest in order to 35 provide ultrasonic images of a vessel or other subcutaneous features.

FIGS. 6A and 6B depict further details regarding the ultrasound probe 70 depicted in FIG. 5. The probe 70 has a general pancake shape and includes a flexible, annular perimeter portion 76 that is configured to be deformable. A reinforcement ring 78 is embedded within the perimeter portion 76 so as to limit the range of deformation for the probe 70. In one embodiment, the reinforcement ring 78 can be configured to maintain the deformation of the probe 70 when deformed by 45 a clinician in order to conform to a particular body contour of the patient.

A transducer **80** is included in the central portion of the probe **70** such that it is bounded by the perimeter portion **76**. In the present embodiment, the transducer **80** includes polyvinylidene fluoride ("pvdf"), which is a non-reactive and pure thermoplastic fluoropolymer that is also a piezoelectric material. As such, the pvdf material can serve as a transducer element for the transducer **80** in producing and detecting ultrasonic signals. Like the perimeter portion **76**, the pvdf transducer is also flexible. The flexible nature of the perimeter portion **76** and the pvdf transducer **80** thus enables the probe to conform to body contours when it is placed upon the body of the patient.

FIG. 6B shows that the probe 70 further includes a hydrogel slab 90 that is positioned on a bottom surface of the transducer 80 so as to provide an acoustically transparent interface between the transducer and the body of the patient. In the present embodiment, the hydrogel slab 90 is manufactured as described herein so as to exhibit ruggedized characteristics and be able to withstand high-energy sterilization procedures. Thus, the hydrogel slab 90 of FIG. 6B shows one

10

example of an optional use of the ruggedized hydrogel product described herein in addition to implementations already described

FIG. 7 shows the pancake ultrasound probe 70 according to another embodiment, wherein the transducer includes a plurality of discrete transducer elements 94 that are physically and electrically isolated separated from one another by insulting dividers 96 of plastic or other suitable material. These and other transducer designs are therefore contemplated. In one embodiment, the probe 70 is employed in an A-mode ultrasound imaging setting to detect the presence of pneumothorax in a patient following the placement of a catheter of other device into the vasculature of the patient in the case where the device has punctured the lung. Differences noted in the A-mode ultrasound profile of the subcutaneous area of interest before and after catheter placement can indicate the presence of pneumothorax. Of course, the probe can be employed in other applications.

Embodiments of the invention may be embodied in other specific forms without departing from the spirit of the present disclosure. The described embodiments are to be considered in all respects only as illustrative, not restrictive. The scope of the embodiments is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

What is claimed is:

- 1. A cap for an ultrasound probe, comprising:
- a body defining a cavity into which a portion of an ultrasound probe is received; and
- a ruggedized low-friction hydrogel insert operably attached to the body, the low-friction hydrogel insert comprising:
 - a gel component including carrageenan gum and konjac gum;

isopropyl alcohol;

deionized water; and

- a free radical absorber component for absorbing free radicals produced when the low-friction hydrogel insert is subjected to a high-energy sterilization procedure, the free radical absorber component including at least one of potassium metabisulfite and ascorbic acid.
- 2. The cap as defined in claim 1, wherein the free radical absorber component includes both potassium metabisulfite and ascorbic acid.
 - 3. An ultrasound probe, comprising
 - a body including a transducer; and
 - a ruggedized hydrogel product operably attached to the body to provide for a low friction interface, the hydrogel product comprising:

a gel component;

isopropyl alcohol;

deionized water; and

- a free radical absorber component for absorbing free radicals produced if the hydrogel product is subjected to at least one of a gamma beam sterilization procedure and an electronic beam sterilization procedure.
- 4. The probe as defined in claim 3, wherein the free radical absorber component includes at least one of potassium metabisulfite and ascorbic acid and wherein the gel component includes a gum component.
- **5**. The probe as defined in claim **3**, wherein the probe is a flexible pancake probe and wherein the hydrogel product is slab-shaped and positioned on a bottom surface of the pancake probe.

6. The probe as defined in claim **5**, wherein the pancake probe includes a flexible outer perimeter that bounds a flexible transducer, the transducer including polyvinylidene fluoride

7. The probe as defined in claim 6, wherein the transducer 5 is segmented into a plurality of discrete transducer elements.

* * * * *